Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
Patent Information
- Application Number
- JP2024114638
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-06-19
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 2024161379000023 
Figure 2024161379000024 
Figure 2024161379000025
Abstract
Description
[Technical field]
[0001] The present invention relates to solid forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone (Compound 1) in substantially crystalline or amorphous form, pharmaceutical compositions thereof, and methods of treatment therewith. The present invention relates to the HCl, HBr, oxalate, maleate, fumarate, and mesylate salts of (Compound 1), as well as solid forms of said salts in substantially crystalline form, pharmaceutical compositions thereof, and methods of treatment therewith. 2. Background of the Invention [Background technology]
[0002] 2. Background of the Invention Protein kinases constitute one of the largest families of human enzymes and regulate many different signaling processes by adding phosphate groups to proteins (T. Hunter, Cell 1987 50:823-829). Specifically, tyrosine kinases phosphorylate the phenolic moiety of tyrosine residues in proteins. The tyrosine kinase family includes members that control cell growth, migration, and differentiation. Abnormal kinase activity is associated with a variety of human diseases, including cancer, autoimmune diseases, and inflammatory diseases. Because protein kinases are common among the master regulators of cell signaling, they provide targets for modulating cell function with small molecule kinase inhibitors, and thus are good drug targets. In addition to treating kinase-mediated disease processes, selective and effective inhibitors of kinase activity are also useful for investigating cell signaling processes and identifying other cellular targets of therapeutic interest.
[0003] There is good evidence that B cells play a major role in the treatment of autoimmune and / or inflammatory diseases. Protein-based therapies that deplete B cells, such as Rituxan, are effective against autoantibody-driven inflammatory diseases, such as rheumatoid arthritis (Rastetter et al. Annu Rev Med 2004 55:477). Therefore, inhibitors of protein kinases that play a role in B cell activation should be useful therapies for B cell-mediated disease pathology, such as autoantibody production.
[0004] Signaling through the B cell receptor (BCR) controls a range of B cell responses, including proliferation and differentiation into mature antibody-producing cells. The BCR is the main control point for B cell activity, and abnormal signaling can cause deregulated B cell proliferation and the formation of pathogenic autoantibodies, leading to multiple autoimmune and / or inflammatory diseases. Bruton's tyrosine kinase (BTK) is a non-BCR-associated kinase that is membrane proximal and immediately downstream from the BCR. Absence of BTK has been shown to block BCR signaling, and thus inhibition of BTK may be a useful therapeutic approach to block B cell-mediated disease processes. BTK has also been reported to play a role in apoptosis (Islam and Smith Immunol. Rev. 2000 178:49), and thus BTK inhibitors would be useful in the treatment of certain B cell lymphomas and leukemias (Feldhahn et al. J. Exp. Med. 2005 201:1837).
[0005] BTK is a member of the Tec family of tyrosine kinases and has been shown to be a critical regulator of early B cell development and mature B cell activation and survival (Khan et al. Immunity 1995 3:283;Ellmeier et al. J. Exp. Med. 2000 192:1611). Mutations in BTK in humans lead to the disease X-linked agammaglobulinemia (XLA) (reviewed in Rosen et al. New Eng. J. Med. 1995 333:431 and Lindvall et al. Immunol. Rev. 2005 203:200). These patients are immunocompromised and show impaired B cell maturation, reduced immunoglobulin and peripheral B cell levels, diminished T cell-independent immune responses, and impaired calcium mobilization following BCR stimulation.
[0006] Evidence for the role of BTK in autoimmune and inflammatory diseases is also provided by BTK-deficient mouse models. In preclinical mouse models of systemic lupus erythematosus (SLE), BTK-deficient mice show a marked amelioration of disease progression. In addition, BTK-deficient mice are resistant to collagen-induced arthritis (Jansson and Holmdahl Clin. Exp. Immunol. 1993 94:459). Selective BTK inhibitors have demonstrated dose-dependent efficacy in mouse arthritis models (Z. Pan et al., Chem. Med Chem. 2007 2:58-61).
[0007] BTK is also expressed by cells other than B cells that may be involved in disease processes. BTK is a major component of Fc-gamma signaling in myeloid cells. For example, BTK is expressed by mast cells, and BTK-deficient bone marrow-derived mast cells demonstrate impaired antigen induced degranulation (Iwaki et al. J. Biol. Chem. 2005 280:40261). This indicates that BTK may be useful in treating pathological mast cell responses such as allergy and asthma. Monocytes from XLA patients with no BTK activity also show reduced TNF-alpha production following stimulation (Horwood et al. J Exp Med 197:1603, 2003). Thus, TNF-alpha-mediated inflammation may be modulated by small molecule BTK inhibitors. Summary of the Invention
[0008] SUMMARY OF THE PRESENT APPLICATION It has now been found that solid forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone (Compound 1), and pharma- ceutically acceptable compositions thereof, are effective as inhibitors of BTK.
[0009] In one aspect, compound 1 is substantially crystalline and in salt-free form, designated form A2, as described and characterized herein. In one aspect, compound 1 is substantially crystalline and in salt-free form, designated form A1, as described and characterized herein. In one aspect, compound 1 is substantially crystalline and in salt-free form, designated form HCl-NF1, as described and characterized herein. In one aspect, compound 1 is substantially crystalline and in salt-free form, designated form HCl-NF2, as described and characterized herein. In one aspect, compound 1 is substantially crystalline and in salt-free form, designated form HCl-NF3, as described and characterized herein. In one aspect, compound 1 is substantially crystalline and in salt-free form, designated form HBr-NF1, as described and characterized herein. In one aspect, compound 1 is substantially crystalline and in salt-free form, designated form HBr-NF2, as described and characterized herein. In one aspect, compound 1 is the oxalate form Oxalic Acid-NF1. In one aspect, compound 1 is the maleate form Maleic Acid-NF1. In one aspect, compound 1 is the maleate form Maleic Acid-NF2. In one aspect, compound 1 is the fumarate form Fumaric Acid NF1. In one aspect, compound 1 is the fumarate form Fumaric Acid NF2. In one aspect, compound 1 is the fumarate form Fumaric Acid NF3. In one aspect, compound 1 is the fumarate form Fumaric Acid NF4. In one aspect, compound 1 is the fumarate form Fumaric Acid NF5. In one aspect, compound 1 is the mesylate form Mesylic Acid-NF1.
[0010] Properties of a solid that are relevant to its effectiveness as a drug may depend on the form the solid is in. For example, in a drug substance, variations in solid form may lead to differences in properties such as melting point, dissolution rate, oral absorption, bioavailability, toxicology results, and clinical trial results.
[0011] Some advantages of the solid forms below include the following:
[0012] A1: Crystalline form with extremely good crystallinity; high thermal stability (mp~160 o C);Slightly hygroscopic according to Ph.Eur. (section 5.11).
[0013] A2: Crystalline form with extremely good crystallinity; high thermal stability (mp~168 o C);Slightly hygroscopic according to Ph.Eur. (section 5.11).
[0014] Hydrochloride form HCl-NF1: Crystalline form with very good crystallinity; High thermal stability (mp / dec~200 o C); slightly hygroscopic according to Ph.Eur. (section 5.11); 1:1 salt stoichiometry; high dissolution level (2h) in biorelevant intestinal media compared to the crystalline solvent-free form A1; FaSSIF approximately 4-fold higher than A1.
[0015] Hydrochloride form HCl-NF2: crystalline form; high thermal stability (mp / dec~192 o C); 1:1 salt stoichiometry
[0016] Hydrochloride form HCl-NF3: Crystalline form with very good crystallinity; High thermal stability (mp / dec~200 o C); 1:1 salt stoichiometry.
[0017] Hydrobromide form HBr-NF1: A crystalline form with very good crystallinity; high thermal stability (mp / dec~203 o C); slightly hygroscopic according to Ph.Eur. (section 5.11); 1:1 salt stoichiometry; high dissolution level (2h) in biorelevant intestinal media compared to the crystalline solvent-free form A1; FaSSIF approximately 3-fold higher than A1.
[0018] Hydrobromide form HBr-NF2: crystalline form; high thermal stability (mp / dec ~173 o C); slightly hygroscopic according to Ph.Eur. (section 5.11); 1:1 salt stoichiometry.
[0019] Oxalate form NF1: A crystalline form with extremely good crystallinity; high thermal stability (mp / dec ~173 o C); slightly hygroscopic according to Ph.Eur. (section 5.11); 1:0.5 salt stoichiometry; high dissolution level (2h) in biorelevant intestinal media compared to the crystalline solvent-free form A1; FaSSIF approximately 4-fold higher than A1.
[0020] Maleate form NF1: A crystalline form with extremely good crystallinity; high thermal stability (mp / dec~139 o C); slightly hygroscopic according to Ph.Eur. (section 5.11); 1:1 salt stoichiometry.
[0021] Maleate salt form NF2: A crystalline form with very good crystallinity; 1:1 salt stoichiometry.
[0022] Fumarate form NF1: crystalline form; high thermal stability (mp / dec~173 o C); slightly hygroscopic according to Ph.Eur. (section 5.11); 1:1 salt stoichiometry; high dissolution level (2h) in biologically relevant intestinal medium compared to the crystalline solvent-free form A1; FaSSIF approximately 2-fold higher than A1.
[0023] Fumarate form NF2: A crystalline form with good crystallinity; high thermal stability (phase transition ~90 o C; Transition to NF-1); 1:1 salt stoichiometry.
[0024] Fumarate form NF3: A crystalline form with extremely good crystallinity; high thermal stability (phase transition ~70 o C; Transition to NF-1); 1:1 salt stoichiometry.
[0025] Fumarate form NF4: A crystalline form with good crystallinity; high thermal stability (mp / dec~140 o C).
[0026] Fumarate form NF5: crystalline form; high thermal stability (mp / dec~158 o C); 1:1 salt stoichiometry.
[0027] Mesylate-salt form NF1: Crystalline form with good crystallinity; high thermal stability (mp / dec~196 o C); slightly hygroscopic according to Ph.Eur. (section 5.11); 1:1 salt stoichiometry.
[0028] The solid forms of Compound 1, and pharma- ceutically acceptable compositions thereof, are useful for treating a variety of diseases, disorders, or conditions associated with BTK, including those described herein. [Brief description of the drawings]
[0029] [Figure 1] Figure 1: Powder X-ray diffractogram of form A1.
[0030] [Diagram 2] Figure 2: Single crystal structure of free base form A1 viewed approximately along the A axis.
[0031] [Diagram 3] Figure 3: DSC scan (5K / min) of free base form A1.
[0032] [Figure 4] Figure 4: TGA scan (5K / min) of free base form A1.
[0033] [Diagram 5] Figure 5: Water vapor sorption isotherm of free base form A1 (25 °C).
[0034] [Figure 6] Figure 6: Powder X-ray diffractogram of free base form A1.
[0035] [Figure 7] FIG. 7: Single crystal structure of free base form A2 viewed approximately along the A axis.
[0036] [Figure 8] Figure 8: DSC scan (5K / min) of free base form A2.
[0037] [Figure 9] Figure 9: TGA scan (5K / min) of free base form A2.
[0038] [Figure 10] FIG. 10: Water vapor sorption isotherm of free base form A2 (25° C.).
[0039] [Figure 11] Figure 11: Powder X-ray diffractogram of the hydrochloride salt form HCl-NF1.
[0040] [Figure 12] Figure 12: DSC scan (5K / min) of the hydrochloride salt form HCl-NF1.
[0041] [Figure 13] Figure 13: TGA scan (5K / min) of the hydrochloride salt form HCl-NF1.
[0042] [Figure 14]FIG. 14: Water vapor sorption isotherm of the hydrochloride salt form HCl-NF1 (25° C.).
[0043] [Figure 15] Figure 15: Powder X-ray diffractogram of the hydrochloride salt form HCl-NF2.
[0044] [Figure 16] Figure 16: DSC scan (5K / min) of the hydrochloride salt form HCl-NF2.
[0045] [Figure 17] Figure 17: TGA scan (5K / min) of the hydrochloride salt form HCl-NF2.
[0046] [Figure 18] Figure 18: Powder X-ray diffractogram of the hydrochloride salt form HCl-NF3.
[0047] [Figure 19] Figure 19: DSC scan (5K / min) of the hydrochloride salt form HCl-NF3.
[0048] [Figure 20] Figure 20: TGA scan (5K / min) of the hydrochloride salt form HCl-NF3.
[0049] [Figure 21] Figure 21: Powder X-ray diffractogram of the hydrobromide salt form HBr-NF1.
[0050] [Figure 22] Figure 22: DSC scan (5K / min) of the hydrobromide salt form HBr-NF1.
[0051] [Figure 23] Figure 23: TGA scan (5K / min) of the hydrobromide salt form HBr-NF1.
[0052] [Figure 24]Figure 24: Water vapor sorption isotherm of the hydrobromide salt form HBr-NF1 (25 °C).
[0053] [Diagram 25] Figure 25: Powder X-ray diffractogram of the hydrobromide salt form HBr-NF2.
[0054] [Figure 26] Figure 26: DSC scan (5K / min) of the hydrobromide salt form HBr-NF2.
[0055] [Figure 27] Figure 27: TGA scan (5K / min) of the hydrobromide salt form HBr-NF2.
[0056] [Figure 28] FIG. 28: Water vapor sorption isotherm of the hydrobromide salt form HBr-NF2 (25° C.).
[0057] [Figure 29] Figure 29: Powder X-ray diffractogram of the oxalate salt form Oxalic Acid-NF1.
[0058] [Diagram 30] Figure 30: DSC scan (5K / min) of the oxalate form Oxalic Acid-NF1.
[0059] [Diagram 31] Figure 31: TGA scan (5K / min) of the oxalate form Oxalic Acid-NF1.
[0060] [Diagram 32] Figure 32: Water vapor sorption isotherm (25 °C) of the oxalate form Oxalic Acid-NF1.
[0061] [Diagram 33] Figure 33: Powder X-ray diffractogram of the maleate salt form Maleic acid-NF1.
[0062] [Diagram 34]Figure 34: DSC scan (5K / min) of the maleate salt form Maleic acid-NF1.
[0063] [Diagram 35] Figure 35: TGA scan (5K / min) of maleate salt form Maleic acid-NF1.
[0064] [Diagram 36] FIG. 36: Water vapor sorption isotherm (25° C.) of maleate salt form Maleic acid-NF1.
[0065] [Figure 37] Figure 37: Powder X-ray diffractogram of the maleate salt form Maleate-NF2.
[0066] [Figure 38] Figure 38: Powder X-ray diffractogram of fumarate salt form Fumaric acid NF1.
[0067] [Figure 39] Figure 39: DSC scan (5K / min) of fumarate salt form Fumaric acid NF1.
[0068] [Diagram 40] Figure 40: TGA scan (5K / min) of fumarate salt form Fumaric acid NF1.
[0069] [Diagram 41] FIG. 41: Water vapor sorption isotherm of fumarate salt form of fumaric acid NF1 (25° C.).
[0070] [Diagram 42] Figure 42: Powder X-ray diffractogram of fumarate salt form Fumaric acid NF2.
[0071] [Diagram 43] Figure 43: DSC scan (5K / min) of fumarate salt form Fumaric acid NF2.
[0072] [Diagram 44]Figure 44: TGA scan (5K / min) of fumarate salt form Fumaric acid NF2.
[0073] [Diagram 45] Figure 45: Powder X-ray diffractogram of fumarate salt form Fumaric acid NF3.
[0074] [Diagram 46] Figure 46: DSC scan (5K / min) of fumarate salt form Fumaric acid NF3.
[0075] [Figure 47] Figure 47: TGA scan (5K / min) of fumarate salt form Fumaric acid NF3.
[0076] [Figure 48] Figure 48: Powder X-ray diffractogram of fumarate salt form Fumaric acid NF4.
[0077] [Figure 49] Figure 49: DSC scan (5K / min) of fumarate salt form fumaric acid NF4.
[0078] [Figure 50] Figure 50: TGA scan (5K / min) of fumarate salt form fumaric acid NF4.
[0079] [Figure 51] Figure 51: Powder X-ray diffractogram of fumarate salt form Fumaric acid NF5.
[0080] [Figure 52] Figure 52: DSC scan (5K / min) of fumarate salt form fumaric acid NF5.
[0081] [Figure 53] Figure 53: TGA scan (5K / min) of fumarate salt form fumaric acid NF5.
[0082] [Figure 54]Figure 54: Powder X-ray diffractogram of the mesylate salt form Mesylate-NF1.
[0083] [Figure 55] Figure 55: DSC scan (5K / min) of mesylate form Mesylate-NF1.
[0084] [Figure 56] Figure 56: TGA scan (5K / min) of mesylate form Mesylate-NF1.
[0085] [Figure 57] Figure 57: Water vapor sorption isotherm of mesylate form Mesylate-NF1 (25°C).
[0086] DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS 1. General Description of the Compounds of the Invention In some aspects, the present invention provides inhibitors of BTK. In some embodiments, such compounds include those represented by the formulas described herein, or pharma- ceutically acceptable salts thereof, wherein each of the variables is as defined and described herein.
[0087] 2. Compounds and Definitions As used herein, the term "amorphous" refers to a solid form consisting of a disordered arrangement of molecules and possessing no discernible crystal lattice.
[0088] "Crystalline" as used herein refers to a compound or composition in which the structural units are arranged in a fixed geometric pattern or lattice such that a crystalline solid can have strict long-range order. The structural units that make up a crystalline structure can be atoms, molecules, or ions. Crystalline solids exhibit a definite melting point.
[0089] The term "chemically stable" as used herein means that the solid form of Compound 1 is not decomposed into one or more different chemical compounds when subjected to specified conditions, e.g., 40°C / 75% relative humidity, for a specified period of time, e.g., 1 day, 2 days, 3 days, 1 week, 2 weeks, or longer. In some embodiments, less than 25% of the solid form of Compound 1 is decomposed, and in some embodiments, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 3%, less than about 1%, less than about 0.5% of the form of Compound 1 is decomposed under the specified conditions. In some embodiments, a non-detectable amount of the solid form of Compound 1 is decomposed.
[0090] The term "physically stable" as used herein means that the solid form of Compound 1 does not change to one or more different physical Compound 1 forms (e.g., different solid forms as measured by XRPD, DSC, etc.) when subjected to specified conditions, e.g., 40°C / 75% relative humidity, for a specified period of time, e.g., 1 day, 2 days, 3 days, 1 week, 2 weeks, or longer. In some embodiments, less than 25% of the solid form of Compound 1 changes to one or more different physical forms when subjected to the specified conditions. In some embodiments, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 3%, less than about 1%, less than about 0.5% of the solid form of Compound 1 changes to one or more different physical Compound 1 forms when subjected to the specified conditions. In some embodiments, a non-detectable amount of the solid form of Compound 1 changes to one or more physically different solid forms of Compound 1.
[0091] As used herein, the phrase "substantially amorphous compound 1" is used interchangeably with the phrases "amorphous compound 1," "amorphous compound 1 substantially free of crystalline compound 1," and "substantially amorphous 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone." In some embodiments, substantially amorphous compound 1 has less than about 30% crystalline compound 1, e.g., less than about 30% crystalline compound 1, e.g., less than about 25% crystalline compound 1, less than about 20% crystalline compound 1, less than about 15% crystalline compound 1, less than about 10% crystalline compound 1, less than about 5% crystalline compound 1, less than about 2% crystalline compound 1.
[0092] As used herein, the phrase "substantially crystalline Compound 1" is used interchangeably with the phrases "Compound 1" and "crystalline Compound 1 substantially free of amorphous Compound 1". In some embodiments, substantially crystalline Compound 1 has less than about 30% amorphous Compound 1 or other solid form, such as less than about 30% amorphous Compound 1 or other solid form, for example, less than about 25% amorphous Compound 1 or other solid form, less than about 20% amorphous Compound 1 or other solid form, less than about 15% amorphous Compound 1 or other solid form, less than about 10% amorphous Compound 1 or other solid form, less than about 5% amorphous Compound 1 or other solid form, less than about 2% amorphous Compound 1 or other solid form. In some embodiments, substantially crystalline Compound 1 has less than about 1% amorphous Compound 1 or other solid form.
[0093] The term "substantially free" (as in the phrase "substantially free of Form X"), when referring to a specified solid form of Compound 1 (e.g., an amorphous or crystalline form described herein), means that less than 20% (by weight) of the specified form(s) or co-form(s) (e.g., a crystalline or amorphous form of Compound 1) is present, more preferably, less than 10% (by weight) of the specified form(s) is present, more preferably, less than 5% (by weight) of the specified form(s) is present, and most preferably, less than 1% (by weight) of the specified form(s) is present.
[0094] The term "substantially pure," when referring to a designated solid form of Compound 1 (e.g., an amorphous solid form or a crystalline solid form described herein), means that the designated solid form contains less than 20% (by weight) of residual components, such as alternate polymorphic or isomorphic crystalline form(s) or mixed form(s) of Compound 1. Preferably, a substantially pure solid form of Compound 1 contains less than 10% (by weight) of alternate polymorphic or isomorphic crystalline Compound 1 forms, more preferably less than 5% (by weight) of alternate polymorphic or isomorphic crystalline Compound 1 forms, and most preferably less than 1% (by weight) of alternate polymorphic or isomorphic crystalline Compound 1 forms.
[0095] As used herein, "dispersion" refers to a dispersion system in which a first substance (dispersed phase) is distributed throughout a second substance (continuous phase or vehicle) in discrete units. The size of the dispersed phase can vary widely (e.g., colloidal particles from nanometer size to multiple microns in size). In general, the dispersed phase can be a solid, liquid, or gas. In the case of solid dispersions, both the dispersed and continuous phases are solids. In pharmaceutical applications, solid dispersions can include crystalline drug (dispersed phase) in an amorphous polymer (continuous phase), or alternatively, amorphous drug (dispersed phase) in an amorphous polymer (continuous phase). In some embodiments, the amorphous solid dispersion includes a polymer that constitutes the dispersed phase, and the drug constitutes the continuous phase. In some embodiments, the dispersion includes amorphous Compound 1 or substantially amorphous Compound 1.
[0096] The term "solid amorphous dispersion" generally refers to a solid dispersion of two or more components, most often a drug and a polymer, but which may also contain other components, such as surfactants or other pharmaceutical excipients, where Compound 1 is amorphous or substantially amorphous (e.g., substantially free of crystalline Compound 1), and where the physical stability and / or solubility and / or dissolution properties of the amorphous drug are enhanced by the other components.
[0097] As used herein, the terms "about" and "approximately", when used in relation to a dose, amount, or weight percentage of a component of a composition or dosage form, refer to a dose, amount, or weight percentage that is recognized by those skilled in the art as providing a pharmacological effect equivalent to that obtained from the specified dose, amount, or weight percentage. Specifically, the term "about" or "approximately" refers to an acceptable error for a specific value as determined by those skilled in the art, which depends in part on how the value is measured or determined. In some embodiments, the terms "about" and "approximately" refer to within 1, 2, 3, or 4 standard deviations. In some embodiments, the term "about" or "approximately" refers to within 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, or 0.05% of a given value or range.
[0098] The abbreviation "XRPD" stands for X-ray powder diffraction.
[0099] The abbreviation "DSC" stands for differential scanning calorimetry.
[0100] The abbreviation "TGA" stands for Thermogravimetric Analysis
[0101] The compounds of the present invention include those generally described above and are further described by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of the present invention, chemical elements are defined as defined in the Periodic Table of the Elements (CAS edition, Handbook of Chemistry and Physics, 75 th In addition, the general principles of organic chemistry are identified in Organic Chemistry (Thomas Sorrell, University Science Books, Sausalito: 1999) and March's Advanced Organic Chemistry (5 thEd., Ed.: Smith, MB and March, J., John Wiley & Sons, New York: 2001), the entire contents of which are incorporated herein by reference.
[0102] As used herein, the term "pharmaceutically acceptable salts" refers to those salts that are suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic reaction, etc., within the scope of sound medical judgment, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include those derived from suitable inorganic and organic acids and bases. Examples of pharma- ceutically acceptable non-toxic acid addition salts are the salts of amino groups formed with inorganic acids such as hydrochloric, hydrobromic, phosphoric, sulfuric, and perchloric acids, or with organic acids such as acetic, oxalic, maleic, tartaric, citric, succinic, or malonic acids, or by using other methods used in the art, such as ion exchange. Other pharma- ceutically acceptable salts are with adipic, alginic, ascorbic, aspartic, benzenesulfonic, benzoic, bisulfate, boric, butyric, camphorate, camphorsulfonate, citric, cyclopentanepropionic, digluconic (di-gluconic), dodecylsulfate, ethanesulfonic, formic, fumaric, glucoheptonic, glycerophosphoric, gluconic, hemisulfate, heptanoic, hexanoic, iodine, and the like. Examples of suitable salts of acetic acid include benzoic acid, 2-hydroxy-ethanesulfonic acid, lactobionic acid, lactic acid, lauric acid, lauryl sulfate, malic acid, maleic acid, malonic acid, methanesulfonic acid, 2-naphthalenesulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, pectinate, persulfate, 3-phenylpropionic acid, phosphoric acid, pivalic acid, propionic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, undecanoic acid, and valeric acid.
[0103] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1~4 Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Additionally, pharma- ceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations formed, where appropriate, using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkylsulfonates, and arylsulfonates.
[0104] Unless so stated, structures depicted herein are also intended to encompass all isomers of that structure (e.g., enantiomers, diastereomers, and geometric isomers (or conformational isomers)); for example, the R and S configurations for each asymmetric center, the Z and E double bond isomers, and the Z and E conformational isomers. Thus, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric isomeric (or conformational isomer) mixtures of the present compounds are within the scope of the invention. Unless so stated, all tautomers of the compounds of the invention are within the scope of the invention.
[0105] As used herein, the term "modulator" is defined as a compound that binds to a target with measurable affinity and / or inhibits a target. In certain embodiments, a modulator has an IC of less than about 50 μM, less than about 1 μM, less than about 500 nM, less than about 100 nM, or less than about 10 nM. 50 and / or has a binding constant.
[0106] The terms "measurable affinity" and "measurably inhibit," as used herein, refer to a measurable change in BTK activity between a sample containing a compound of the present invention or a composition thereof and BTK, and a comparable sample containing BTK (in the absence of the compound or composition thereof).
[0107] 3. Description of exemplary compounds According to one aspect, the present invention provides a compound 1 in solid form, JPEG2024161379000001.jpg9699, or a pharma- ceutically acceptable salt thereof.
[0108] In certain aspects, the invention provides solid form A2 of Compound 1, solid form A1 of Compound 1, the HCl salt HCl-NF1 of Compound 1, the HCl salt HCl-NF2 of Compound 1, the HCl salt HCl-NF3 of Compound 1, the HBr salt HBr-NF1 of Compound 1, the HBr salt HBr-NF2 of Compound 1, the oxalate form oxalic acid-NF1 of Compound 1, the maleate form maleic acid-NF1 of Compound 1, the maleate form maleate-NF2 of Compound 1, the fumarate form fumaric acid NF1 of Compound 1, the fumarate form fumaric acid NF2 of Compound 1, the fumarate form fumaric acid NF3 of Compound 1, the fumarate form fumaric acid NF4 of Compound 1, the fumarate form fumaric acid NF5 of Compound 1, or the mesylate form mesylate-NF1 of Compound 1.
[0109] In one embodiment, the present invention provides compound 1, characterized as crystalline form A1.
[0110] In some embodiments, form A1 is characterized by one or more 2θ peaks at 17.4 and 20.0 degrees. In some embodiments, form A1 is characterized by one or more 2θ peaks at 17.1, 17.4, 18.8, 20.0, and 21.1 degrees. In some embodiments, form A1 is characterized by two or more 2θ peaks at 17.1, 17.4, 18.8, 20.0, and 21.1 degrees. In some embodiments, form A1 is characterized by three or more 2θ peaks at 17.1, 17.4, 18.8, 20.0, and 21.1 degrees. In some embodiments, form A1 is characterized by four or more 2θ peaks at 17.1, 17.4, 18.8, 20.0, and 21.1 degrees. In some embodiments, form A1 is characterized by two or more 2θ peaks at 17.1, 17.4, 18.8, 20.0, and 21.1 degrees.
[0111] In some embodiments, Form A1 is [Table 1] It is characterized by a 2θ peak at
[0112] In another embodiment, form A1 is characterized by a diffraction pattern substantially similar to FIG.
[0113] The powder X-ray diffraction pattern of the free base form A2 was obtained from the European Pharmacopeia 6 th The powder was obtained by standard techniques as described in the International Publication No. 2003 / 013363 and characterized by the following X-ray powder diffractogram (monochromated Cu-Kα1 radiation, λ=1.5406 Å, Stoe StadiP 611 KL transmission diffractometer):
[0114] In certain embodiments, Form A1 is characterized by a crystalline form having a monoclinic space group P21 / n with lattice parameters (298K) a=12.8483(4) Å, b=12.8585(3) Å, c=28.5734(9) Å, and β=97.950(3)° (with α=γ=90°). Rationally rounded, the parameters are a=12.8±0.1 Å, b=12.9±0.1 Å, c=28.6±0.1 Å, and β=98.0±0.1° (with α=γ=90°). The single crystal structure reveals that Form A1 represents an anhydrous form. Single crystal X-ray structure data was also obtained for the free base Form A1 (Cu K at 298 K from Agilent). a The SuperNova diffractometer is equipped with a CCD detector that uses radiation.
[0115] In some embodiments, Form A1 is an anhydrous form.
[0116] Other physical properties of Form A1 include:The thermal behavior of Form A1 showed a melting peak onset at about 160°C. Thermogravimetric analysis revealed a low weight loss of about 0.2% m / m up to this temperature. The DSC and TGA profiles are displayed below. DSC scans of Form A1 were obtained on a Mettler-Toledo DSC1 at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. TGA scans of Form A1 were obtained on a Mettler-Toledo TGA851 at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. The water vapor sorption behavior of Form A1 showed water uptake levels of ≦1% m / m in the relative humidity (rh) range of 0-80% rh, and slightly elevated water uptake levels of ≦2% m / m in the relative humidity (rh) range of 90-98% rh. Form A1 can be classified as slightly hygroscopic according to the Ph.Eur. Criteria (section 5.11). The water vapor sorption isotherm (25°C) of Form A1 is provided in the figure. The water vapor sorption isotherm was obtained on a DVS-specific system from SMS. The thermodynamic solubility (24h) of Form A1 at 37°C was determined to be about 17 μg / mL in Fasted-State Simulated Intestinal Fluid [FaSSIF, pH 6.5] and about 1 μg / mL in USP phosphate buffer [pH 7.4], respectively (see Example 6). The dissolution level of Form A1 in Fasted-State Simulated Intestinal Fluid [FaSSIF, pH 6.5] at 37°C was determined to be about 17 μg / mL after 2h (see Example 7). Overall, free base form A1 exhibited good solid state properties (good crystallinity, slightly hygroscopic, high thermal stability) with good manufacturability on a larger scale.
[0117] In one aspect, the present invention is characterized as crystalline form A2.
[0118] In some embodiments, form A2 is characterized by one or more 2θ e peaks at 17.0, 18.7, and 21.7 degrees. In some embodiments, form A2 is characterized by two or more 2θ peaks at 17.0, 18.7, and 21.7 degrees. In some embodiments, form A2 is characterized by 2θ peaks at 17.0, 18.7, and 21.7 degrees.
[0119] In some embodiments, form A2 is characterized by one or more 2θ peaks at 7.5, 10.8, 17.0, 17.5, 18.7, 20.5, 21.7, 22.3, 23.6, and 24.0 degrees. In some embodiments, form A2 is characterized by two or more 2θ peaks at 7.5, 10.8, 17.0, 17.5, 18.7, 20.5, 21.7, 22.3, 23.6, and 24.0 degrees. In some embodiments, form A2 is characterized by three or more 2θ peaks at 7.5, 10.8, 17.0, 17.5, 18.7, 20.5, 21.7, 22.3, 23.6, and 24.0 degrees. In some embodiments, form A2 is characterized by 4 or more 2θ peaks at 7.5, 10.8, 17.0, 17.5, 18.7, 20.5, 21.7, 22.3, 23.6, and 24.0 degrees. In some embodiments, form A2 is characterized by 5 or more 2θ peaks at 7.5, 10.8, 17.0, 17.5, 18.7, 20.5, 21.7, 22.3, 23.6, and 24.0 degrees. In some embodiments, form A2 is characterized by 6 or more 2θ peaks at 7.5, 10.8, 17.0, 17.5, 18.7, 20.5, 21.7, 22.3, 23.6, and 24.0 degrees. In some embodiments, form A2 is characterized by 7 or more 2θ peaks at 7.5, 10.8, 17.0, 17.5, 18.7, 20.5, 21.7, 22.3, 23.6, and 24.0 degrees. In some embodiments, form A2 is characterized by 7 or more 2θ peaks at 7.5, 10.8, 17.0, 17.5, 18.7, 20.5, 21.7, 22.3, 23.6, and 24.0 degrees.
[0120] In some embodiments, Form A2 is [Table 2] It is characterized by a 2θ peak at
[0121] In another embodiment, form A2 is characterized by a diffraction pattern substantially similar to that of FIG.
[0122] The powder X-ray diffraction pattern of the free base form A2 was obtained from the European Pharmacopeia 6 th The powder was obtained by standard techniques as described in the US Pat. No. 5,393,411 and characterized by the following X-ray powder diffractogram (monochromated Cu-Kα1 radiation, λ=1.5406 Å, Stoe StadiP 611 KL transmission diffractometer):
[0123] In certain embodiments, Form A2 crystallizes in the triclinic space group P-1 with lattice parameters (at 200 K) a=9.5326(12) Å, b=10.7284(14) Å, c=12.7734(16) Å, and α=70.960(12)°, β=68.852(11)°, γ=71.900(11)°. Rationally rounded, the parameters are a=9.5±0.1A, b=10.7±0.1A, c=12.8±0.1A, and α=71.0±0.1°, β=68.9±0.1°, γ=71.9±0.1°. From the single crystal structure, it is apparent that Form A2 represents an anhydrous form.
[0124] In some embodiments, Form A2 is an anhydrous form. In some embodiments, free base Form A2 is a crystalline anhydrous form.
[0125] Other physical properties of Form A2 include: The T thermal behavior of Form A2 showed a melting peak onset at about 168°C. Thermogravimetric analysis revealed a low weight loss of about 0.2% m / m up to this temperature. DSC and TGA profiles are displayed in the figures. DSC scans of Form A2 were obtained on a Mettler-Toledo DSC821e at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. TGA scans of Form A2 were obtained on a Mettler-Toledo TGA851 at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. The water vapor sorption behavior of Form A2 showed a water uptake level of ≦1% m / m in the relative humidity (rh) range of 0-80% rh, and a very slightly elevated water uptake level of ≦2% m / m in the relative humidity (rh) range of 90-98% rh. Form A2 can be classified as slightly hygroscopic according to the Ph.Eur. Criteria (section 5.11). The water vapor sorption isotherm (25°C) of Form A2 is displayed below. The water vapor sorption isotherm was obtained on a DVS-specific system from SMS. The thermodynamic solubility (24h) of Form A2 at 37°C was determined to be about 10 μg / mL in Fasted-State Simulated Intestinal Fluid [FaSSIF, pH 6.5] and about 2 μg / mL in USP phosphate buffer [pH 7.4], respectively (see Example 6). The dissolution level of Form A2 in Fasted-State Simulated Intestinal Fluid [FaSSIF, pH 6.5] at 37°C was determined to be about 8 μg / mL after 2h (see Example 7). Overall, free base form A2 exhibited good solid state properties (good crystallinity, slightly hygroscopic, high thermal stability) with good manufacturability on a larger scale.
[0126] In one embodiment, the present invention provides compound 1, characterized as the hydrochloride salt form, HCl-NF1.
[0127] In some embodiments, form HCl-NF1 is characterized by one or more of 2θ peaks at 15.7, 19.1, 20.3, and 20.8 degrees. In some embodiments, form HCl-NF1 is characterized by two or more of 2θ peaks at 15.7, 19.1, 20.3, and 20.8 degrees. In some embodiments, form HCl-NF1 is characterized by 2θ peaks at 15.7, 19.1, 20.3, and 20.8 degrees.
[0128] In some embodiments, form HCl-NF1 is characterized by one or more of 2θ peaks at 10.3, 13.7, 15.7, 19.1, 20.3, 20.8, and 21.9 degrees. In some embodiments, form HCl-NF1 is characterized by two or more of 2θ peaks at 10.3, 13.7, 15.7, 19.1, 20.3, 20.8, and 21.9 degrees. In some embodiments, form HCl-NF1 is characterized by three or more of 2θ peaks at 10.3, 13.7, 15.7, 19.1, 20.3, 20.8, and 21.9 degrees. In some embodiments, form HCl-NF1 is characterized by four or more of 2θ peaks at 10.3, 13.7, 15.7, 19.1, 20.3, 20.8, and 21.9 degrees. In some embodiments, form HCl-NF1 is characterized by 5 or more of 2θ peaks at 10.3, 13.7, 15.7, 19.1, 20.3, 20.8, and 21.9 degrees. In some embodiments, form HCl-NF1 is characterized by 6 or more of 2θ peaks at 10.3, 13.7, 15.7, 19.1, 20.3, 20.8, and 21.9 degrees. In some embodiments, form HCl-NF1 is characterized by 2θ peaks at 10.3, 13.7, 15.7, 19.1, 20.3, 20.8, and 21.9 degrees.
[0129] In some embodiments, the form HCl-NF1 is [Table 3] It is characterized by a 2θ peak at
[0130] In another embodiment, form HCl-NF1 is characterized by a diffraction pattern substantially similar to FIG.
[0131] The powder X-ray diffraction pattern of form HCl-NF1 was obtained from the European Pharmacopeia 6 th The powder was obtained by standard techniques as described in the US Pat. No. 5,393,411 and characterized by the following X-ray powder diffractogram (monochromated Cu-Kα1 radiation, λ=1.5406 Å, Stoe StadiP 611 KL transmission diffractometer):
[0132] In another embodiment, form HCl-NF1 is characterized as a crystalline anhydrous form.
[0133] Other physical properties of form HCl-NF1 include: Thermal behavior of hydrochloride form HCl-NF1 showed a melting peak onset at about 200°C. Thermogravimetric analysis revealed a low weight loss of about 0.7% m / m up to this temperature. DSC and TGA profiles are displayed in the figure. DSC scans of hydrochloride form HCl-NF1 were obtained on a Mettler-Toledo DSC821e at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. TGA scans of hydrochloride form HCl-NF1 were obtained on a Mettler-Toledo TGA851 at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. Water vapor sorption behavior of form HCl-NF1 showed a small water uptake level of ≦1% m / m in the relative humidity (rh) range of 0-80% rh, and a slightly elevated water uptake level of ≦5% m / m in the relative humidity (rh) range of 90-98% rh. The hydrochloride salt form HCl-NF1 can be classified as slightly hygroscopic according to the Ph.Eur. Criteria (section 5.11). The water vapor sorption isotherm (25°C) of the hydrochloride salt form HCl-NF1 is displayed in Figure 1. The water vapor sorption isotherm was obtained on a DVS-specific system from SMS. The solubility level of the hydrochloride salt form HCl-NF1 at 37°C was determined to be about 46 μg / mL after 2 h in Fasted-State Simulated Intestinal Fluid [FaSSIF, pH 6.5] (see Example 7). Overall, the hydrochloride salt form HCl-NF1 exhibited good solid-state properties (good crystallinity, slightly hygroscopic, high thermal stability).
[0134] In one embodiment, the present invention is characterized as the hydrochloride salt form HCl-NF2.
[0135] In some embodiments, form HCl-NF2 is characterized by one or more of 2θ peaks at 7.8, 13.0, and 15.6 degrees. In some embodiments, form HCl-NF2 is characterized by two or more of 2θ peaks at 7.8, 13.0, and 15.6 degrees. In some embodiments, form HCl-NF2 is characterized by peaks at 7.8, 13.0, and 15.6 degrees 2θ.
[0136] In some embodiments, form HCl-NF2 is characterized by one or more of 2θ peaks at 6.5, 7.8, 9.1, 13.0, and 22.0 degrees. In some embodiments, form HCl-NF2 is characterized by two or more of 2θ peaks at 6.5, 7.8, 9.1, 13.0, and 22.0 degrees. In some embodiments, form HCl-NF2 is characterized by three or more of 2θ peaks at 6.5, 7.8, 9.1, 13.0, and 22.0 degrees. In some embodiments, form HCl-NF2 is characterized by four or more of 2θ peaks at 6.5, 7.8, 9.1, 13.0, and 22.0 degrees. In some embodiments, form HCl-NF2 is characterized by 2θ peaks at 6.5, 7.8, 9.1, 13.0, and 22.0 degrees.
[0137] In some embodiments, the form HCl-NF2 is [Table 4] It is characterized by a 2θ peak at
[0138] In another embodiment, form HCl-NF2 is characterized by a diffraction pattern substantially similar to FIG.
[0139] The powder X-ray diffraction pattern of form HCl-NF2 is reported in European Pharmacopeia 6 th The powder was obtained by standard techniques as described in the US Pat. No. 5,393,411 and characterized by the following X-ray powder diffractogram (monochromated Cu-Kα1 radiation, λ=1.5406 Å, Stoe StadiP 611 KL transmission diffractometer):
[0140] In another embodiment, form HCl-NF2 is characterized as a crystalline anhydrous form.
[0141] Other physical properties of form HCl-NF2 include: Thermal behavior of the hydrochloride salt form HCl-NF2 showed a melting peak onset at about 192°C. Thermogravimetric analysis showed a low weight loss of about 0.6% m / m up to this temperature. DSC and TGA profiles are displayed in the figures. DSC scans of the hydrochloride salt form HCl-NF2 were obtained on a Mettler-Toledo DSC1 at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. TGA scans of the hydrochloride salt form HCl-NF2 were obtained on a Mettler-Toledo TGA / DSC1 at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. Overall, the hydrochloride salt form HCl-NF2 exhibits good solid state properties (crystallinity, high thermal stability).
[0142] In one embodiment, the present invention provides compound 1, characterized as the hydrochloride salt form, HCl-NF3.
[0143] In some embodiments, form HCl-NF3 is characterized by one or more of 2θ peaks at 14.8, 16.8, 20.1, and 20.4 degrees. In some embodiments, form HCl-NF3 is characterized by two or more of 2θ peaks at 14.8, 16.8, 20.1, and 20.4 degrees. In some embodiments, form HCl-NF3 is characterized by 2θ peaks at 14.8, 16.8, 20.1, and 20.4 degrees.
[0144] In some embodiments, form HCl-NF3 is characterized by one or more of the following 2θ peaks: 9.7, 13.5, 14.8, 16.8, 20.1, 20.4, and 23.0 degrees. In some embodiments, form HCl-NF3 is characterized by two or more of the following 2θ peaks: 9.7, 13.5, 14.8, 16.8, 20.1, 20.4, and 23.0 degrees. In some embodiments, form HCl-NF3 is characterized by three or more of the following 2θ peaks: 9.7, 13.5, 14.8, 16.8, 20.1, 20.4, and 23.0 degrees. In some embodiments, form HCl-NF3 is characterized by four or more of the following 2θ peaks: 9.7, 13.5, 14.8, 16.8, 20.1, 20.4, and 23.0 degrees. In some embodiments, form HCl-NF3 is characterized by 5 or more of the following 2θ peaks: 9.7, 13.5, 14.8, 16.8, 20.1, 20.4, and 23.0 degrees. In some embodiments, form HCl-NF3 is characterized by 6 or more of the following 2θ peaks: 9.7, 13.5, 14.8, 16.8, 20.1, 20.4, and 23.0 degrees. In some embodiments, form HCl-NF3 is characterized by 9.7, 13.5, 14.8, 16.8, 20.1, 20.4, and 23.0 degrees 2θ peaks.
[0145] In some embodiments, the form HCl-NF3 is [Table 5] It is characterized by a 2θ peak at
[0146] In another embodiment, form HCl-NF3 is characterized by a diffraction pattern substantially similar to FIG.
[0147] The powder X-ray diffraction pattern of the form HCl-NF3 is reported in the European Pharmacopeia 6 thThe powder was obtained by standard techniques as described in the US Pat. No. 5,393,411 and characterized by the following X-ray powder diffractogram (monochromated Cu-Kα1 radiation, λ=1.5406 Å, Stoe StadiP 611 KL transmission diffractometer):
[0148] In another embodiment, form HCl-NF3 is characterized as a crystalline solvate form.
[0149] Other physical properties of form HCl-NF3 include: Thermal behavior of the hydrochloride salt form HCl-NF3 showed a melting peak onset at about 200°C. Thermogravimetric analysis showed a weight loss of about 7% m / m up to this temperature. DSC and TGA profiles are displayed in the figures. DSC scans of the hydrochloride salt form HCl-NF3 were obtained on a Mettler-Toledo 821e at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. TGA scans of the hydrochloride salt form HCl-NF3 were obtained on a Mettler-Toledo TGA851 at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. Overall, the hydrochloride salt form HCl-NF3 exhibits good solid state properties (crystallinity, high thermal stability).
[0150] In one embodiment, the present invention provides compound 1, characterized as the hydrobromide salt form, HBr-NF1.
[0151] In some embodiments, form HBr-NF1 is characterized by one or more of 2θ peaks at 6.9, 19.1, 20.4, 20.8, and 21.9 degrees. In some embodiments, form HBr-NF1 is characterized by two or more of 2θ peaks at 6.9, 19.1, 20.4, 20.8, and 21.9 degrees. In some embodiments, form HBr-NF1 is characterized by 2θ peaks at 6.9, 19.1, 20.4, 20.8, and 21.9 degrees.
[0152] In some embodiments, form HBr-NF1 is characterized by one or more of 2θ peaks at 6.9, 13.6, 15.5, 16.5, 19.1, 20.4, 20.8, 21.9, and 23.5 degrees. In some embodiments, form HBr-NF1 is characterized by two or more of 2θ peaks at 6.9, 13.6, 15.5, 16.5, 19.1, 20.4, 20.8, 21.9, and 23.5 degrees. In some embodiments, form HBr-NF1 is characterized by three or more of 2θ peaks at 6.9, 13.6, 15.5, 16.5, 19.1, 20.4, 20.8, 21.9, and 23.5 degrees. In some embodiments, form HBr-NF1 is characterized by 4 or more of the 2θ peaks at 6.9, 13.6, 15.5, 16.5, 19.1, 20.4, 20.8, 21.9, and 23.5 degrees. In some embodiments, form HBr-NF1 is characterized by 5 or more of the 2θ peaks at 6.9, 13.6, 15.5, 16.5, 19.1, 20.4, 20.8, 21.9, and 23.5 degrees. In some embodiments, form HBr-NF1 is characterized by 6 or more of the 2θ peaks at 6.9, 13.6, 15.5, 16.5, 19.1, 20.4, 20.8, 21.9, and 23.5 degrees. In some embodiments, form HBr-NF1 is characterized by 7 or more of theta peaks at 6.9, 13.6, 15.5, 16.5, 19.1, 20.4, 20.8, 21.9, and 23.5 degrees. In some embodiments, form HBr-NF1 is characterized by 7 or more of theta peaks at 6.9, 13.6, 15.5, 16.5, 19.1, 20.4, 20.8, 21.9, and 23.5 degrees.
[0153] In some embodiments, the form HBr-NF3 is [Table 6] It is characterized by a 2θ peak at
[0154] In another embodiment, form HBr-NF1 is characterized by a diffraction pattern substantially similar to FIG.
[0155] The powder X-ray diffraction pattern of the free base form HBr-NF1 was obtained from the European Pharmacopeia 6 th The powder was obtained by standard techniques as described in the US Pat. No. 5,393,411 and characterized by the following X-ray powder diffractogram (monochromated Cu-Kα1 radiation, λ=1.5406 Å, Stoe StadiP 611 KL transmission diffractometer):
[0156] In another embodiment, form HBr-NF1 is characterized as a crystalline anhydrous form.
[0157] Other physical properties of form HBr-NF1 include: Thermal behavior of the hydrobromide salt form HBr-NF1 showed a melting peak onset at about 203°C. Thermogravimetric analysis revealed a low weight loss of about 0.8% m / m up to this temperature. DSC and TGA profiles are displayed in the figure. DSC scans of the hydrobromide salt form HBr-NF1 were obtained on a Mettler-Toledo DSC821e at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. TGA scans of the hydrobromide salt form HBr-NF1 were obtained on a Mettler-Toledo TGA851 at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. The water vapor sorption behavior of the hydrobromide salt form HBr-NF1 exhibited a small water uptake level of ≦1% m / m in the relative humidity (rh) range 0-80% rh and a slightly elevated water uptake level of ≦5% m / m in the relative humidity (rh) range 90-98% rh. The hydrobromide salt form HBr-NF1 can be classified as slightly hygroscopic according to the Ph.Eur. Criteria (section 5.11). The water vapor sorption isotherm (25 °C) of the hydrobromide salt form HBr-NF1 is displayed in the figure. The water vapor sorption isotherm was obtained on a DVS-specific system from SMS. The solubility level of the hydrobromide salt form HBr-NF1 in Fasted-State Simulated Intestinal Fluid [FaSSIF, pH 6.5] at 37 °C was determined to be about 35 μg / mL after 2 h (see Example 7). Overall, the hydrobromide salt form HBr-NF1 exhibited good solid-state properties (good crystallinity, slightly hygroscopic, high thermal stability).
[0158] In one embodiment, the present invention provides compound 1, specifically identified as the hydrobromide salt form, HBr-NF2.
[0159] In some embodiments, form HBr-NF2 is characterized by one or more of 2θ peaks at 4.9, 13.2, and 20.0 degrees. In some embodiments, form HBr-NF2 is characterized by two or more of 2θ peaks at 4.9, 13.2, and 20.0 degrees. In some embodiments, form HBr-NF2 is characterized by peaks at 4.9, 13.2, and 20.0 degrees 2θ.
[0160] In some embodiments, form HBr-NF2 is characterized by one or more of 2θ peaks at 4.9, 7.5, 13.2, 20.0, and 20.6 degrees. In some embodiments, form HBr-NF2 is characterized by two or more of 2θ peaks at 4.9, 7.5, 13.2, 20.0, and 20.6 degrees. In some embodiments, form HBr-NF2 is characterized by three or more of 2θ peaks at 4.9, 7.5, 13.2, 20.0, and 20.6 degrees. In some embodiments, form HBr-NF2 is characterized by four or more of 2θ peaks at 4.9, 7.5, 13.2, 20.0, and 20.6 degrees. In some embodiments, form HBr-NF2 is characterized by two or more of 2θ peaks at 4.9, 7.5, 13.2, 20.0, and 20.6 degrees.
[0161] In some embodiments, the form HBr-NF2 is [Table 7] It is characterized by a 2θ peak at
[0162] In another embodiment, form HBr-NF2 is characterized by a diffraction pattern substantially similar to FIG.
[0163] The powder X-ray diffraction pattern of the free base form HBr-NF2 was reported in the European Pharmacopeia 6 thThe powder was obtained by standard techniques as described in the International Publication No. 2003 / 013363 and characterized by the following X-ray powder diffractogram (monochromated Cu-Kα1 radiation, λ=1.5406 Å, Stoe StadiP 611 KL transmission diffractometer):
[0164] In another embodiment, form HBr-NF2 is characterized as a crystalline anhydrous form.
[0165] Other physical properties of form HBr-NF2 include: Thermal behavior of the hydrobromide salt form HBr-NF2 showed a melting peak onset at about 173°C. Thermogravimetric analysis revealed a weight loss of about 1.3% m / m up to this temperature. DSC and TGA profiles are displayed in the figures. DSC scans of the hydrobromide salt form HBr-NF2 were obtained on a Mettler-Toledo DSC821e at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. TGA scans of the hydrobromide salt form HBr-NF2 were obtained on a Mettler-Toledo TGA / DSC1 at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. The water vapor sorption behavior of the hydrobromide salt form HBr-NF2 exhibited a small water uptake level ≦1%m / m in the relative humidity (rh) range 0-80%rh and an elevated water uptake level ≧5%m / m in the relative humidity (rh) range 90-98%rh. The hydrobromide salt form HBr-NF2 can be classified as slightly hygroscopic according to the Ph.Eur. Criteria (section 5.11). The water vapor sorption isotherm (25°C) of the hydrobromide salt form HBr-NF2 is displayed in the figure. The water vapor sorption isotherm was obtained on a DVS-specific system from SMS. Overall, the hydrobromide salt form HBr-NF2 exhibited good solid state properties (good crystallinity, slightly hygroscopic, high thermal stability).
[0166] In one embodiment, the present invention provides compound 1, characterized as the oxalate form Oxalic acid-NF1.
[0167] In some embodiments, the form Oxalic Acid-NF1 is characterized by one or more of 2θ peaks at 16.2, 17.7, 18.6, 21.1, and 21.3 degrees. In some embodiments, the form Oxalic Acid-NF1 is characterized by two or more of 2θ peaks at 16.2, 17.7, 18.6, 21.1, and 21.3 degrees. In some embodiments, the form Oxalic Acid-NF1 is characterized by 2θ peaks at 16.2, 17.7, 18.6, 21.1, and 21.3 degrees.
[0168] In some embodiments, the form Oxalic Acid-NF1 is characterized by one or more of the following 2θ peaks: 8.2, 10.4, 13.0, 16.2, 17.7, 18.6, 21.1, 21.3, and 23.2 degrees. In some embodiments, the form Oxalic Acid-NF1 is characterized by two or more of the following 2θ peaks: 8.2, 10.4, 13.0, 16.2, 17.7, 18.6, 21.1, 21.3, and 23.2 degrees. In some embodiments, the form Oxalic Acid-NF1 is characterized by three or more of the following 2θ peaks: 8.2, 10.4, 13.0, 16.2, 17.7, 18.6, 21.1, 21.3, and 23.2 degrees. In some embodiments, the form Oxalic Acid-NF1 is characterized by 4 or more of the 2θ peaks at 8.2, 10.4, 13.0, 16.2, 17.7, 18.6, 21.1, 21.3, and 23.2 degrees. In some embodiments, the form Oxalic Acid-NF1 is characterized by 5 or more of the 2θ peaks at 8.2, 10.4, 13.0, 16.2, 17.7, 18.6, 21.1, 21.3, and 23.2 degrees. In some embodiments, the form Oxalic Acid-NF1 is characterized by 6 or more of the 2θ peaks at 8.2, 10.4, 13.0, 16.2, 17.7, 18.6, 21.1, 21.3, and 23.2 degrees. In some embodiments, the form Oxalic Acid-NF1 is characterized by 7 or more of the 2θ peaks at 8.2, 10.4, 13.0, 16.2, 17.7, 18.6, 21.1, 21.3, and 23.2 degrees. In some embodiments, the form Oxalic Acid-NF1 is characterized by 7 or more of the 2θ peaks at 8.2, 10.4, 13.0, 16.2, 17.7, 18.6, 21.1, 21.3, and 23.2 degrees.
[0169] In some embodiments, the form oxalate-NF1 is [Table 8] It is characterized by a 2θ peak at
[0170] In another embodiment, the form Oxalic Acid-NF1 is characterized by a diffraction pattern substantially similar to FIG.
[0171] The powder X-ray diffraction pattern of the free base form of oxalic acid-NF1 was obtained from the European Pharmacopeia 6 th The powder was obtained by standard techniques as described in the International Publication No. 2003 / 013363 and characterized by the following X-ray powder diffractogram (monochromated Cu-Kα1 radiation, λ=1.5406 Å, Stoe StadiP 611 KL transmission diffractometer):
[0172] In another embodiment, the form Oxalic Acid-NF1 is characterized as a crystalline anhydrous form.
[0173] Other physical properties of form Oxalic Acid-NF1 include: Thermal behavior of the oxalate form Oxalic Acid-NF1 showed a melting peak onset at about 173°C. Thermogravimetric analysis revealed a weight loss of about 1.2% m / m up to this temperature. DSC and TGA profiles are displayed in the figure. DSC scans of the oxalate form Oxalic Acid-NF1 were obtained on a Mettler-Toledo DSC821e at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. TGA scans of the oxalate form Oxalic Acid-NF1 were obtained on a Mettler-Toledo TGA851 at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. The water vapor sorption behavior of the oxalate form of Oxalic Acid-NF1 exhibited a small water uptake level of ≦1% m / m in the relative humidity (rh) range of 0-80% rh and a slightly elevated water uptake level of ≦5% m / m in the relative humidity (rh) range of 90-98% rh. The oxalate form of Oxalic Acid-NF1 can be classified as slightly hygroscopic according to the Ph.Eur. Criteria (section 5.11). The water vapor sorption isotherm (25 °C) of the oxalate form of Oxalic Acid-NF1 is displayed in the figure. The water vapor sorption isotherm was obtained on a DVS-specific system from SMS. The solubility level of the oxalate form of Oxalic Acid-NF1 in Fasted-State Simulated Intestinal Fluid [FaSSIF, pH 6.5] at 37 °C was determined to be about 53 μg / mL after 2 h (see Example 7). Overall, the oxalate form Oxalic Acid-NF1 exhibited good solid-state properties (good crystallinity, slightly hygroscopic, high thermal stability).
[0174] In one embodiment, the present invention provides compound 1, characterized as the maleate salt form Maleic acid-NF1.
[0175] In some embodiments, the form Maleic Acid-NF1 is characterized by one or more of 2θ peaks at 18.1, 19.1, 20.8, and 24.8 degrees. In some embodiments, the form Maleic Acid-NF1 is characterized by two or more of 2θ peaks at 18.1, 19.1, 20.8, and 24.8 degrees. In some embodiments, the form Maleic Acid-NF1 is characterized by 2θ peaks at 18.1, 19.1, 20.8, and 24.8 degrees.
[0176] In some embodiments, the form Maleic Acid-NF1 is characterized by one or more of the following 2θ peaks: 6.5, 10.3, 11.5, 12.8, 18.1, 18.7, 19.1, 20.8, and 24.8 degrees. In some embodiments, the form Maleic Acid-NF1 is characterized by two or more of the following 2θ peaks: 6.5, 10.3, 11.5, 12.8, 18.1, 18.7, 19.1, 20.8, and 24.8 degrees. In some embodiments, the form Maleic Acid-NF1 is characterized by three or more of the following 2θ peaks: 6.5, 10.3, 11.5, 12.8, 18.1, 18.7, 19.1, 20.8, and 24.8 degrees. In some embodiments, the form Maleic Acid-NF1 is characterized by 4 or more of the 2θ peaks at 6.5, 10.3, 11.5, 12.8, 18.1, 18.7, 19.1, 20.8, and 24.8 degrees. In some embodiments, the form Maleic Acid-NF1 is characterized by 5 or more of the 2θ peaks at 6.5, 10.3, 11.5, 12.8, 18.1, 18.7, 19.1, 20.8, and 24.8 degrees. In some embodiments, the form Maleic Acid-NF1 is characterized by 6 or more of the 2θ peaks at 6.5, 10.3, 11.5, 12.8, 18.1, 18.7, 19.1, 20.8, and 24.8 degrees. It is characterized by 7 or more of the following peaks at 12.8, 18.1, 18.7, 19.1, 20.8, and 24.8 degrees 2θ. In some embodiments, form Maleic-NF1 is characterized by peaks at 6.5, 10.3, 11.5, 12.8, 18.1, 18.7, 19.1, 20.8, and 24.8 degrees 2θ.
[0177] In some embodiments, the form maleic acid-NF1 is [Table 9] It is characterized by a 2θ peak at
[0178] In another embodiment, the form Maleic-NF1 is characterized by a diffraction pattern substantially similar to FIG.
[0179] The powder X-ray diffraction pattern of the free base form of maleic acid-NF1 was obtained from the European Pharmacopeia 6 th The powder was obtained by standard techniques as described in the International Publication No. 2003 / 013363 and characterized by the following X-ray powder diffractogram (monochromated Cu-Kα1 radiation, λ=1.5406 Å, Stoe StadiP 611 KL transmission diffractometer):
[0180] In another embodiment, the form Maleic-NF1 is characterized as a crystalline anhydrous form.
[0181] Other physical properties of Form Maleic Acid-NF1 include: Thermal behavior of the maleate salt form Maleic Acid-NF1 showed a melting peak onset at about 139°C. Thermogravimetric analysis revealed a weight loss of about 0.7% m / m up to this temperature. DSC and TGA profiles are displayed in the figure. DSC scans of the maleate salt form Maleic Acid-NF1 were obtained on a Mettler-Toledo DSC821e at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. TGA scans of the maleate salt form Maleic Acid-NF1 were obtained on a Mettler-Toledo TGA851 at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. The water vapor sorption behavior of the maleate form of maleic acid-NF1 exhibited a small water uptake level of ≦1% m / m in the relative humidity (rh) range 0-80% rh and a slightly elevated water uptake level of ≦5% m / m in the relative humidity (rh) range 90-98% rh. The maleate form of maleic acid-NF1 can be classified as slightly hygroscopic according to the Ph.Eur. Criteria (section 5.11). The water vapor sorption isotherm (25 °C) of the maleate form of maleic acid-NF1 is displayed in the figure. The water vapor sorption isotherm was obtained on a DVS-specific system from SMS. Overall, the maleate form of maleic acid-NF1 exhibited good solid state properties (good crystallinity, slightly hygroscopic, high thermal stability).
[0182] In one embodiment, the present invention provides compound 1, characterized as the maleate salt form Maleic acid-NF2.
[0183] In some embodiments, the form Maleic-NF2 is characterized by one or more of 2θ peaks at 10.8, 17.1, 19.2, and 20.7 degrees 2θ. In some embodiments, the form Maleic-NF2 is characterized by two or more of 2θ peaks at 10.8, 17.1, 19.2, and 20.7 degrees 2θ. In some embodiments, the form Maleic-NF2 is characterized by peaks at 10.8, 17.1, 19.2, and 20.7 degrees 2θ.
[0184] In some embodiments, the form Maleic Acid-NF2 is characterized by one or more of the following 2θ peaks: 8.5, 10.8, 17.1, 18.1, 18.5, 19.2, 20.7, 21.7, and 23.2 degrees. In some embodiments, the form Maleic Acid-NF2 is characterized by two or more of the following 2θ peaks: 8.5, 10.8, 17.1, 18.1, 18.5, 19.2, 20.7, 21.7, and 23.2 degrees. In some embodiments, the form Maleic Acid-NF2 is characterized by three or more of the following 2θ peaks: 8.5, 10.8, 17.1, 18.1, 18.5, 19.2, 20.7, 21.7, and 23.2 degrees. In some embodiments, the form Maleic Acid-NF2 is characterized by 4 or more of the 2θ peaks at 8.5, 10.8, 17.1, 18.1, 18.5, 19.2, 20.7, 21.7, and 23.2 degrees. In some embodiments, the form Maleic Acid-NF2 is characterized by 5 or more of the 2θ peaks at 8.5, 10.8, 17.1, 18.1, 18.5, 19.2, 20.7, 21.7, and 23.2 degrees. In some embodiments, the form Maleic Acid-NF2 is characterized by 6 or more of the 2θ peaks at 8.5, 10.8, 17.1, 18.1, 18.5, 19.2, 20.7, 21.7, and 23.2 degrees. In some embodiments, the form Maleic Acid-NF2 is characterized by 7 or more of the following 2θ peaks: 8.5, 10.8, 17.1, 18.1, 18.5, 19.2, 20.7, 21.7, and 23.2 degrees 2θ. In some embodiments, the form Maleic Acid-NF2 is characterized by 7 or more of the following 2θ peaks: 8.5, 10.8, 17.1, 18.1, 18.5, 19.2, 20.7, 21.7, and 23.2 degrees 2θ peaks.
[0185] In some embodiments, the form maleic acid-NF2 is [Table 10] It is characterized by a 2θ peak at
[0186] In another embodiment, the form Maleic-NF2 is characterized by a diffraction pattern substantially similar to FIG.
[0187] The powder X-ray diffraction pattern of the free base form of maleic acid-NF2 was obtained from the European Pharmacopeia 6 th The powder was obtained by standard techniques as described in the International Publication No. 2003 / 013363 and characterized by the following X-ray powder diffractogram (monochromated Cu-Kα1 radiation, λ=1.5406 Å, Stoe StadiP 611 KL transmission diffractometer):
[0188] In another embodiment, the form Maleic-NF2 is characterized as a crystalline form.
[0189] In one aspect, the present invention provides compound 1, characterized as the fumarate form Fumarate-NF1.
[0190] In some embodiments, the form Fumaric Acid-NF1 is characterized by one or more of 2θ peaks at 9.0, 17.0, 18.4, and 22.1 degrees. In some embodiments, the form Fumaric Acid-NF1 is characterized by two or more of 2θ peaks at 9.0, 17.0, 18.4, and 22.1 degrees. In some embodiments, the form Fumaric Acid-NF1 is characterized by 2θ peaks at 9.0, 17.0, 18.4, and 22.1 degrees.
[0191] In some embodiments, the form Fumaric Acid-NF1 is characterized by one or more of 2θ peaks at 9.0, 16.7, 17.0, 18.4, 18.7, 20.9, and 22.1 degrees. In some embodiments, the form Fumaric Acid-NF1 is characterized by two or more of 2θ peaks at 9.0, 16.7, 17.0, 18.4, 18.7, 20.9, and 22.1 degrees. In some embodiments, the form Fumaric Acid-NF1 is characterized by three or more of 2θ peaks at 9.0, 16.7, 17.0, 18.4, 18.7, 20.9, and 22.1 degrees. In some embodiments, the form Fumaric Acid-NF1 is characterized by four or more of 2θ peaks at 9.0, 16.7, 17.0, 18.4, 18.7, 20.9, and 22.1 degrees. In some embodiments, form Fumaric Acid-NF1 is characterized by 5 or more of the following 2θ peaks: 9.0, 16.7, 17.0, 18.4, 18.7, 20.9, and 22.1 degrees 2θ. In some embodiments, form Fumaric Acid-NF1 is characterized by the following 2θ peaks: 9.0, 16.7, 17.0, 18.4, 18.7, 20.9, and 22.1 degrees 2θ.
[0192] In some embodiments, the form fumarate-NF1 is [Table 11] It is characterized by a 2θ peak at
[0193] In another embodiment, the form Fumaric Acid-NF1 is characterized by a diffraction pattern substantially similar to FIG.
[0194] The powder X-ray diffraction pattern of the free base form of fumaric acid-NF1 was obtained from the European Pharmacopeia 6 th The powder was obtained by standard techniques as described in the International Publication No. 2003 / 013363 and characterized by the following X-ray powder diffractogram (monochromated Cu-Kα1 radiation, λ=1.5406 Å, Stoe StadiP 611 KL transmission diffractometer):
[0195] In another embodiment, the form Fumaric acid-NF1 is characterized as a crystalline anhydrous form. Other physical properties of the fumarate form Fumaric acid-NF1 include: Thermal behavior of the fumarate salt form Fumaric acid-NF1 showed a melting peak onset at about 173°C. Thermogravimetric analysis revealed a low weight loss of about 0.3% m / m up to this temperature. DSC and TGA profiles are displayed in the figures. DSC scans of the fumarate salt form Fumaric acid-NF1 were obtained on a Mettler-Toledo DSC821e at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. TGA scans of the fumarate salt form Fumaric acid-NF1 were obtained on a Mettler-Toledo TGA851 at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. The water vapor sorption behavior of the fumarate salt form of Fumaric Acid-NF1 exhibited a small water uptake level of ≦1% m / m in the relative humidity (rh) range of 0-80% rh and an elevated water uptake level of ≧5% m / m in the relative humidity (rh) range of 90-98% rh. Fumarate salt form of Fumaric Acid-NF1 can be classified as slightly hygroscopic according to the Ph.Eur. Criteria (section 5.11). The water vapor sorption isotherm (25°C) of the fumarate salt form of Fumaric Acid-NF1 is displayed in the figure. The water vapor sorption isotherm was obtained on a DVS-specific system from SMS. The solubility level of the fumarate salt form of Fumaric Acid-NF1 in Fasted-State Simulated Intestinal Fluid [FaSSIF, pH 6.5] at 37°C was determined to be about 27 μg / mL after 2 h (see Example 7). Overall, the fumarate salt form Fumaric acid-NF1 exhibited good solid-state properties (good crystallinity, slightly hygroscopic, high thermal stability).
[0196] In one aspect, the present invention provides compound 1, characterized as the fumarate form Fumarate-NF2.
[0197] In some embodiments, the form Fumaric acid-NF2 is characterized by one or more of 2θ peaks at 18.4, 19.2, and 20.3 degrees. In some embodiments, the form Fumaric acid-NF2 is characterized by two or more of 2θ peaks at 18.4, 19.2, and 20.3 degrees. In some embodiments, the form Fumaric acid-NF2 is characterized by 2θ peaks at 18.4, 19.2, and 20.3 degrees.
[0198] In some embodiments, the form Fumaric acid-NF2 is characterized by one or more of 2θ peaks at 9.6, 10.6, 13.9, 14.9, 18.4, 19.2, and 20.3 degrees. In some embodiments, the form Fumaric acid-NF2 is characterized by two or more of 2θ peaks at 9.6, 10.6, 13.9, 14.9, 18.4, 19.2, and 20.3 degrees. In some embodiments, the form Fumaric acid-NF2 is characterized by three or more of 2θ peaks at 9.6, 10.6, 13.9, 14.9, 18.4, 19.2, and 20.3 degrees. In some embodiments, the form Fumaric acid-NF2 is characterized by four or more of 2θ peaks at 9.6, 10.6, 13.9, 14.9, 18.4, 19.2, and 20.3 degrees. In some embodiments, the form Fumaric acid-NF2 is characterized by 5 or more of the following peaks at 9.6, 10.6, 13.9, 14.9, 18.4, 19.2, and 20.3 degrees 2θ.
[0199] In some embodiments, the form fumarate-NF2 is [Table 12] It is characterized by a 2θ peak at
[0200] In another embodiment, the form Fumaric acid-NF2 is characterized by a diffraction pattern substantially similar to FIG.
[0201] The powder X-ray diffraction pattern of the free base form of fumaric acid-NF2 was obtained from the European Pharmacopeia 6 thThe powder was obtained by standard techniques as described in the International Publication No. 2003 / 013363 and characterized by the following X-ray powder diffractogram (monochromated Cu-Kα1 radiation, λ=1.5406 Å, Stoe StadiP 611 KL transmission diffractometer):
[0202] In another embodiment, the form Fumaric acid-NF2 is characterized as a crystalline solvate form.
[0203] Other physical properties of fumarate form Fumaric acid-NF2 include: Thermal behavior of fumarate form Fumaric acid-NF2 showed a phase transition to fumarate form Fumaric acid-NF1 at about 90°C and a melting peak onset of about 172°C for fumarate form Fumaric acid-NF1. Thermogravimetric analysis showed a weight loss of about 6% m / m up to this temperature. DSC and TGA profiles are displayed in the figure. DSC scans of fumarate form Fumaric acid-NF2 were obtained on a Mettler-Toledo DSC821e at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. TGA scans of fumarate form Fumaric acid-NF2 were obtained on a Mettler-Toledo TGA851 at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. Overall, fumarate form Fumaric acid-NF2 showed good solid state properties (good crystallinity, slightly hygroscopic, high thermal stability).
[0204] In one embodiment, the present invention provides compound 1, characterized as the fumarate salt form Fumaric acid-NF3.
[0205] In some embodiments, the form Fumaric acid-NF3 is characterized by one or more of 2θ peaks at 6.9, 10.3, 17.4, and 21.1 degrees. In some embodiments, the form Fumaric acid-NF3 is characterized by two or more of 2θ peaks at 6.9, 10.3, 17.4, and 21.1 degrees. In some embodiments, the form Fumaric acid-NF3 is characterized by 2θ peaks at 6.9, 10.3, 17.4, and 21.1 degrees.
[0206] In some embodiments, the form Fumaric acid-NF3 is characterized by one or more of 2θ peaks at 6.9, 10.3, 17.4, 21.1, 21.4, and 25.7 degrees. In some embodiments, the form Fumaric acid-NF3 is characterized by two or more of 2θ peaks at 6.9, 10.3, 17.4, 21.1, 21.4, and 25.7 degrees. In some embodiments, the form Fumaric acid-NF3 is characterized by three or more of 2θ peaks at 6.9, 10.3, 17.4, 21.1, 21.4, and 25.7 degrees. In some embodiments, the form Fumaric acid-NF3 is characterized by four or more of 2θ peaks at 6.9, 10.3, 17.4, 21.1, 21.4, and 25.7 degrees. In some embodiments, the form Fumaric acid-NF3 is characterized by 5 or more of the following peaks at 6.9, 10.3, 17.4, 21.1, 21.4, and 25.7 degrees 2θ. In some embodiments, the form Fumaric acid-NF3 is characterized by the following peaks at 6.9, 10.3, 17.4, 21.1, 21.4, and 25.7 degrees 2θ.
[0207] In some embodiments, the form fumarate-NF3 is [Table 13] It is characterized by a 2θ peak at
[0208] In another embodiment, the form Fumaric acid-NF3 is characterized by a diffraction pattern substantially similar to FIG.
[0209] The powder X-ray diffraction pattern of the free base form of fumaric acid-NF3 was obtained from the European Pharmacopeia 6 th The powder was obtained by standard techniques as described in the International Publication No. 2003 / 013363 and characterized by the following X-ray powder diffractogram (monochromated Cu-Kα1 radiation, λ=1.5406 Å, Stoe StadiP 611 KL transmission diffractometer):
[0210] In another embodiment, the form Fumaric acid-NF3 is characterized as a crystalline solvate form.
[0211] Other physical properties of fumarate form Fumaric acid-NF3 include: Thermal behavior of fumarate form Fumaric acid-NF3 showed a phase transition to fumarate form Fumaric acid-NF1 at about 70°C and a melting peak onset of about 170°C for fumarate form Fumaric acid-NF1. Thermogravimetric analysis showed a weight loss of about 14% m / m up to this temperature. DSC and TGA profiles are displayed in the figure. DSC scans of fumarate form Fumaric acid-NF3 were obtained on a Mettler-Toledo DSC821e at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. TGA scans of fumarate form Fumaric acid-NF3 were obtained on a Mettler-Toledo TGA851 at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. Overall, fumarate form Fumaric acid-NF3 showed good solid state properties (good crystallinity, high thermal stability).
[0212] In one embodiment, the present invention provides compound 1, characterized as the fumarate salt form Fumaric acid-NF4.
[0213] In some embodiments, the form Fumaric acid-NF4 is characterized by one or more of 2θ peaks at 7.9, 15.8, 18.4, and 19.4 degrees. In some embodiments, the form Fumaric acid-NF4 is characterized by two or more of 2θ peaks at 7.9, 15.8, 18.4, and 19.4 degrees. In some embodiments, the form Fumaric acid-NF4 is characterized by 2θ peaks at 7.9, 15.8, 18.4, and 19.4 degrees.
[0214] In some embodiments, the form Fumaric acid-NF4 is characterized by one or more of the following 2θ peaks: 7.9, 8.9, 11.7, 12.9, 15.8, 18.4, 19.4, and 21.8 degrees. In some embodiments, the form Fumaric acid-NF4 is characterized by two or more of the following 2θ peaks: 7.9, 8.9, 11.7, 12.9, 15.8, 18.4, 19.4, and 21.8 degrees. In some embodiments, the form Fumaric acid-NF4 is characterized by three or more of the following 2θ peaks: 7.9, 8.9, 11.7, 12.9, 15.8, 18.4, 19.4, and 21.8 degrees. In some embodiments, the form Fumaric acid-NF4 is characterized by 4 or more of 2θ peaks at 7.9, 8.9, 11.7, 12.9, 15.8, 18.4, 19.4, and 21.8 degrees. In some embodiments, the form Fumaric acid-NF4 is characterized by 5 or more of 2θ peaks at 7.9, 8.9, 11.7, 12.9, 15.8, 18.4, 19.4, and 21.8 degrees. In some embodiments, the form Fumaric acid-NF4 is characterized by 2θ peaks at 7.9, 8.9, 11.7, 12.9, 15.8, 18.4, 19.4, and 21.8 degrees.
[0215] In some embodiments, the form fumarate-NF4 is [Table 14] It is characterized by a 2θ peak at
[0216] In another embodiment, the form Fumaric acid-NF4 is characterized by a diffraction pattern substantially similar to FIG.
[0217] The powder X-ray diffraction pattern of the free base form fumaric acid-NF4 was obtained from the European Pharmacopeia 6 th The powder was obtained by standard techniques as described in the International Publication No. 2003 / 013363 and characterized by the following X-ray powder diffractogram (monochromated Cu-Kα1 radiation, λ=1.5406 Å, Stoe StadiP 611 KL transmission diffractometer):
[0218] In another embodiment, the form Fumaric acid-NF4 is characterized as a crystalline solvate form.
[0219] Other physical properties of fumarate form Fumaric acid-NF4 include: Thermal behavior of fumarate salt form Fumaric acid-NF4 showed a melting peak onset of about 140°C. Thermogravimetric analysis showed a low weight loss of about 3%m / m up to this temperature. DSC and TGA profiles are displayed in the figure. DSC scans of fumarate salt form Fumaric acid-NF4 were obtained on a Mettler-Toledo DSC821e at a heating rate of 5K / min using nitrogen purge gas at 50mL / min. TGA scans of fumarate salt form Fumaric acid-NF4 were obtained on a Mettler-Toledo TGA851 at a heating rate of 5K / min using nitrogen purge gas at 50mL / min. Overall, fumarate salt form Fumaric acid-NF4 showed good solid state properties (good crystallinity, high thermal stability).
[0220] In one embodiment, the present invention provides compound 1, characterized as the fumarate salt form Fumaric acid-NF5.
[0221] In some embodiments, the form Fumaric acid-NF5 is characterized by one or more of 2θ peaks at 16.0, 19.8, 22.2, and 23.4 degrees. In some embodiments, the form Fumaric acid-NF5 is characterized by two or more of 2θ peaks at 16.0, 19.8, 22.2, and 23.4 degrees. In some embodiments, the form Fumaric acid-NF5 is characterized by 2θ peaks at 16.0, 19.8, 22.2, and 23.4 degrees.
[0222] In some embodiments, the form fumaric acid-NF5 is [Table 15] It is characterized by a 2θ peak at
[0223] In another embodiment, the form Fumaric acid-NF5 is characterized by a diffraction pattern substantially similar to FIG.
[0224] The powder X-ray diffraction pattern of the free base form of fumaric acid-NF5 was obtained from the European Pharmacopeia 6 th The powder was obtained by standard techniques as described in the International Publication No. 2003 / 013363 and characterized by the following X-ray powder diffractogram (monochromated Cu-Kα1 radiation, λ=1.5406 Å, Stoe StadiP 611 KL transmission diffractometer): In another embodiment, the form Fumaric acid-NF5 is characterized as a crystalline form.
[0225] Other physical properties of the fumarate form Fumaric acid-NF5 include: The thermal behavior of the fumarate salt form Fumaric acid-NF5 showed a melting peak onset of about 158°C. Thermogravimetric analysis showed a low weight loss of about 3%m / m up to this temperature. DSC and TGA profiles are displayed in the figure. DSC scans of the fumarate salt form Fumaric acid-NF5 were obtained on a Mettler-Toledo DSC821e at a heating rate of 5K / min using nitrogen purge gas at 50mL / min. TGA scans of the fumarate salt form Fumaric acid-NF5 were obtained on a Mettler-Toledo TGA851 at a heating rate of 5K / min using nitrogen purge gas at 50mL / min. Overall, the fumarate salt form Fumaric acid-NF5 showed good solid state properties (crystallinity, high thermal stability).
[0226] In one embodiment, the present invention provides compound 1, characterized as the mesylate salt form mesylate-NF1.
[0227] In some embodiments, the form Mesylate-NF1 is characterized by one or more of 2θ peaks at 18.7, 19.5, and 21.1 degrees. In some embodiments, the form Mesylate-NF1 is characterized by two or more of 2θ peaks at 18.7, 19.5, and 21.1 degrees. In some embodiments, the form Mesylate-NF1 is characterized by 2θ peaks at 18.7, 19.5, and 21.1 degrees.
[0228] In some embodiments, the form Mesylate-NF1 is characterized by one or more of 2θ peaks at 11.2, 12.4, 13.1, 18.7, 19.5, and 21.1 degrees. In some embodiments, the form Mesylate-NF1 is characterized by two or more of 2θ peaks at 11.2, 12.4, 13.1, 18.7, 19.5, and 21.1 degrees. In some embodiments, the form Mesylate-NF1 is characterized by three or more of 2θ peaks at 11.2, 12.4, 13.1, 18.7, 19.5, and 21.1 degrees. In some embodiments, the form Mesylate-NF1 is characterized by four or more of 2θ peaks at 11.2, 12.4, 13.1, 18.7, 19.5, and 21.1 degrees. In some embodiments, the form mesylate-NF1 is characterized by peaks at 11.2, 12.4, 13.1, 18.7, 19.5, and 21.1 degrees 2θ.
[0229] In some embodiments, the form mesylate-NF1 is [Table 16] It is characterized by a 2θ peak at
[0230] In another embodiment, the form Mesylate-NF1 is characterized by a diffraction pattern substantially similar to FIG.
[0231] The powder X-ray diffraction pattern of the free base form of mesylate-NF1 was obtained from the European Pharmacopeia 6 th The powder was obtained by standard techniques as described in the International Publication No. 2003 / 013363 and characterized by the following X-ray powder diffractogram (monochromated Cu-Kα1 radiation, λ=1.5406 Å, Stoe StadiP 611 KL transmission diffractometer):
[0232] In another embodiment, the form mesylate-NF1 is characterized as a crystalline anhydrous form.
[0233] Other physical properties of mesylate form NF1 include: Thermal behavior of mesylate form NF1 showed a melting peak onset of about 196°C. Thermogravimetric analysis revealed a low weight loss of about 0.6% m / m up to this temperature. DSC and TGA profiles are displayed in the figure. DSC scans of mesylate form NF1 were obtained on a Mettler-Toledo DSC821e at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. TGA scans of mesylate form NF1 were obtained on a Mettler-Toledo TGA851 at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min. The water vapor sorption behavior of the mesylate form Mesylic Acid-NF1 exhibited a small water uptake level ≦1%m / m in the relative humidity (rh) range 0-80%rh and a slightly elevated water uptake level ≦5%m / m in the relative humidity (rh) range 90-98%rh. Mesylate form Mesylic Acid-NF1 can be classified as slightly hygroscopic according to the Ph.Eur. Criteria (section 5.11). The water vapor sorption isotherm (25 °C) of the mesylate form Mesylic Acid-NF1 is displayed in Figure 1. The water vapor sorption isotherm was obtained on a DVS-specific system from SMS.
[0234] Overall, the mesylate form Mesylate-NF1 exhibited good solid-state properties (good crystallinity, slightly hygroscopic, high thermal stability).
[0235] In one embodiment, the present invention provides compound 1, characterized as a mixture of crystalline forms A1 and A2.
[0236] The development of solid-state preparation routes has been primarily based on the solvent crystallization approach, which allows scalability to large scale, as well as providing powdered materials with good manufacturability properties.
[0237] Mixtures of morphic forms are not preferred from a regulatory and quality perspective, as the phase composition of the mixture is challenging to control from batch to batch. The variability of the phase composition requires extensive characterization to assess the impact on critical quality attributes (e.g. oral absorption behavior, stability behavior), which may also jeopardize robust DP manufacturability when parameters such as particle habit differ for the various forms and their mixtures.
[0238] Surprisingly, the present invention provides a preparation route for the thermodynamically stable phase-pure crystalline form A2 of compound 1, which provides a powder material with good manufacturability properties on a large scale.
[0239] In another aspect, the invention features a pharmaceutical composition including any of the forms and salts described above and a pharma- ceutical carrier. In another embodiment, the pharmaceutical composition further includes an additional therapeutic agent.
[0240] In another aspect, the invention features a process for preparing Form A1 or A2, comprising dissolving Compound 1 in an organic solvent, water, or a mixture thereof. In some embodiments, the solvent is ethanol, 1-propanol, 2-propanol, 2-butanol, acetone, methyl ethyl ketone, methyl isobutyl ketone, ethyl acetate, 1,4-dioxane, diethyl ether, methyl tert-butyl ether, tetrahydrofuran, acetonitrile, dichloromethane, chloroform, toluene, or pyridine, or a mixture thereof. In some embodiments, the solvent is ethanol, 1-propanol, 1-butanol, iso-butanol, methyl ethyl ketone, methyl isobutyl ketone, ethyl acetate, 1,4-dioxane, diethyl ether, methyl tert-butyl ether, tetrahydrofuran, acetonitrile, dichloromethane, chloroform, N,N-dimethylformamide, toluene, ortho-xylene, para-xylene, or pyridine, or a mixture thereof.
[0241] In certain embodiments, the solvent is ethanol, 2-propanol, acetone, methyl isobutyl ketone, ethyl acetate, acetonitrile, or toluene, or a mixture thereof.
[0242] In some embodiments, compound 1 is dissolved in an organic solvent between about 20-75° C. In some embodiments, compound 1 is dissolved in an organic solvent at about 25° C. In some embodiments, compound 1 is dissolved in an organic solvent at about 50° C.
[0243] In certain embodiments, the invention features a process for preparing Form A2, comprising dissolving Compound 1 or Form A1 of Compound 1 in alcohol, water, or a mixture thereof.
[0244] In some embodiments, the process includes a mixture of alcohol and water, hi some embodiments, the alcohol is methanol, ethanol, or 2-propanol.
[0245] In certain embodiments, the compounds and solid forms of the present invention were synthesized according to the schemes provided in the examples below.
[0246] 4. Use, Formulation and Administration Pharmaceutically acceptable compositions According to another aspect, the present invention provides a composition comprising a solid form of Compound 1 of the present invention or a pharma- ceutically acceptable derivative thereof and a pharma- ceutically acceptable carrier, adjuvant, or vehicle. The amount of the solid form of Compound 1 in the composition of the present invention is an amount effective to measurably inhibit BTK or a mutant thereof in a biological sample or in a patient. In some embodiments, the amount of the solid form of Compound 1 in the composition of the present invention is an amount effective to measurably inhibit BTK or a mutant thereof in a biological sample or in a patient. In some embodiments, the composition of the present invention is formulated for administration to a patient in need of such a composition.
[0247] The terms "patient" or "subject", as used herein, mean an animal, preferably a mammal, and most preferably a human.
[0248] The term "pharmaceutically acceptable carrier, adjuvant, or vehicle" refers to a non-toxic carrier, adjuvant, or vehicle that does not impair the pharmacological activity of the solid form of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants, or vehicles used in the compositions of the present invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wool fat.
[0249] "Pharmaceutically acceptable derivative" means any non-toxic salt, ester, salt of an ester, or other derivative of a compound of the invention that is capable of providing, either directly or indirectly, a compound of the invention, or an inhibitory active metabolite or residue thereof, upon administration to a recipient.
[0250] The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intracisternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally, or intravenously. Sterile injectable forms of the compositions of the present invention include aqueous or oleaginous suspensions. These suspensions are formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic parenterally acceptable diluents or solvents, such as solutions in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.
[0251] For this purpose, any bland fixed oil may be employed, including synthetic mono- or di-glycerides. Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, including natural pharma- ceutically acceptable oils such as olive oil or castor oil, especially their polyoxyethylated versions. These oil solutions or suspensions also contain long-chain alcohol diluents or dispersants, such as carboxymethylcellulose or similar dispersants, which are commonly used in the formulation of pharma- ceutically acceptable dosage forms, including emulsions and suspensions. Other commonly used surfactants, such as Tween, Span and other emulsifiers or bioavailability enhancers, which are commonly used in the manufacture of pharma-ceutically acceptable solid, liquid or other dosage forms, are also used for formulation purposes.
[0252] The pharmaceutically acceptable composition of the present invention can be orally administered in any orally acceptable dosage form. Exemplary oral dosage forms are capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, commonly used carriers include lactose and corn starch. Lubricants such as magnesium stearate are also typically added. Useful diluents for oral administration in capsule form include lactose and dried corn starch. When aqueous suspension is required for oral use, active ingredient is combined with emulsifying and suspending agents. If desired, certain sweeteners, flavorings or colorings are also optionally added.
[0253] Alternatively, the pharma- ceutically acceptable compositions of the present invention are administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient, which is solid at room temperature but liquid at rectal temperature, and will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycols.
[0254] The pharma- ceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
[0255] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
[0256] The pharmaceutically acceptable composition provided for topical use is formulated into a suitable ointment containing active components suspended or dissolved in one or more carriers.The exemplary carriers for topical administration of this compound are mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.Alternatively, the pharmaceutically acceptable composition provided can be formulated into a suitable lotion or cream containing active components suspended or dissolved in one or more pharmaceutically acceptable carriers.Suitable carriers include but are not limited to mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
[0257] The pharma- ceutically acceptable compositions of this invention are optionally administered by nasal aerosol or inhalation.Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and are prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.
[0258] Most preferably, the pharma- ceutically acceptable composition of the present invention is formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, the pharma- ceutically acceptable composition of the present invention is administered without food. In other embodiments, the pharma- ceutically acceptable composition of the present invention is administered with food.
[0259] The amount of the compounds of the present invention that are optionally combined with carrier materials to produce a composition in a single dosage form will vary depending on the host treated, the particular mode of administration. Preferably, the compositions provided should be formulated so that a dosage of between 0.01-100 mg / kg body weight / day of the compound can be administered to a patient receiving these compositions.
[0260] It should also be understood that the specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including the activity of the particular compound employed, age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician, and the severity of the particular disease being treated. The amount of a compound of the invention in a composition will also depend on the particular compound in the composition.
[0261] Uses of the Compounds and Pharmaceutically Acceptable Compositions In certain embodiments, the present invention provides a method for inhibiting BTK or a mutant thereof in a patient or in a biological sample, the method comprising the step of administering to the patient or contacting the biological sample with a solid form of Compound 1 according to the present invention or a pharma- ceutically acceptable salt thereof.
[0262] In some embodiments, the present invention is directed to the use of solid forms of Compound 1 or pharma- ceutically acceptable salts thereof to modulate or inhibit the BTK enzyme. The term "modulation" refers to any change in BTK-mediated signal transduction, which is based on the action of the specific inventive compounds of the present invention that are capable of interacting with the BTK target in a manner that allows recognition, binding, and activation. The compounds are characterized by such high affinity for BTK that they ensure reliable binding of BTK. In some embodiments, the substances are highly selective for BTK over most other kinases, ensuring exclusive and directed recognition of a single BTK target. In the context of the present invention, the term "recognition" refers - without being limited thereto - to any type of interaction between a particular compound and a target, in particular a covalent or non-covalent binding or association, such as a covalent bond, hydrophobic / hydrophilic interaction, van der Waals forces, ion pairs, hydrogen bonds, ligand-receptor (enzyme-inhibitor) interaction, etc. Such associations may also encompass the presence of other molecules, such as peptides, proteins, or nucleotide sequences. The protein / ligand (enzyme-inhibitor)-interactions are characterized by high affinity, high selectivity, and minimal or even lack of cross-reactivity with other target molecules, in order to eliminate unhealthy and harmful impacts on the treated subject.
[0263] In one embodiment, the present invention relates to a method for inhibiting the BTK enzyme with at least a solid form of Compound 1, or a pharma- ceutically acceptable salt thereof, under conditions in which the BTK enzyme can be inhibited. In one embodiment, the system is a cell system. In another embodiment, the system is an in-vitro translation based on protein synthesis without living cells. A cell system is defined for any subject, but the subject includes a cell. Thus, the cell system can be selected from the group of a single cell, a cell culture, a tissue, an organ, and an animal. In one embodiment, the method for modulating the BTK enzyme is performed in-vitro. The teachings herein above regarding the solid form of Compound 1 or a pharma- ceutically acceptable salt thereof (including any of these embodiments) are valid and applicable without limitation to the present compound when the present compound is used in a method for inhibiting BTK. The teachings herein above regarding the solid form of Compound 1 or a pharma- ceutically acceptable salt thereof are valid and applicable without limitation to the present compound when the present compound is used in a method for inhibiting BTK.
[0264] Patients with mutations in BTK have a profound block in B cell development, resulting in an almost complete absence of mature B lymphocytes and plasma cells, severely reduced Ig levels, and profound inhibition of humoral responses to recall antigens (reviewed in Vihinen et al Frontiers in Bioscience 5:d917-928). Mice lacking BTK also have reduced peripheral B cell numbers and greatly reduced serum levels of IgM and IgG3. BTK deletion in mice has profound effects on anti-IgM-induced B cell proliferation and inhibits immune responses to type II thymus-independent antigens (Ellmeier et al, J Exp Med 192:1611-1623 (2000)). BTK also plays a critical role in mast cell activation through the high affinity IgE receptor (Fc epsilon RI). Mast cells from BTK-deficient mice have reduced degranulation and decreased production of pro-inflammatory cytokines following Fc epsilon RI cross-linking (Kawakami et al. Journal of Leukocyte Biology 65:286-290).
[0265] The solid forms of Compound 1, or pharma- ceutically acceptable salts thereof, provided herein are inhibitors of BTK and are therefore useful for treating one or more disorders associated with the activity of BTK. Thus, in some embodiments, the present invention provides methods for treating a BTK-mediated disorder, comprising administering a solid form of Compound 1, or a pharma-ceutically acceptable salt thereof, to a patient in need thereof.
[0266] As used herein, the term "BTK-mediated" disorder or disease, as used herein, means any disease or other deleterious condition in which BTK or a mutant thereof is known to play a role. Accordingly, another aspect of the present invention relates to treating or lessening the severity of one or more diseases in which BTK or a mutant thereof is known to play a role. Specifically, the present invention relates to a method of treating or lessening the severity of a disease or condition selected from a proliferative disorder or an autoimmune disorder, the method comprising administering a compound or composition according to the present invention to a patient in need thereof.
[0267] In some embodiments, the present invention provides a method for treating or lessening the severity of one or more diseases and conditions associated with BTK, where the disease or condition is selected from cancer. In one embodiment, the cancer is a B-cell proliferative disorder, such as diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, acute lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma / Waldenstrom's hypergammaglobulinemia, splenic marginal zone lymphoma, multiple myeloma (also known as plasma cell myeloma), non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmacytoma, extramuscular marginal zone B-cell lymphoma, muscular marginal zone B-cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma / leukemia, or lymphomatoid granulomatosis. In some embodiments, the cancer is breast cancer, prostate cancer, or mast cell cancer (e.g., mastocytoma, mast cell leukemia, mast cell sarcoma, systemic mastocytosis). In one embodiment, the cancer is bone cancer. In another embodiment, the cancer has metastasized to the bone from another primary site. In some embodiments, the cancer is colorectal cancer, or pancreatic cancer.
[0268] In some embodiments, the cancer is non-Hodgkin's lymphoma mantle cell lymphoma or non-Hodgkin's lymphoma diffuse large B-cell lymphoma, including the abc subtype.
[0269] In some embodiments, the present invention provides methods for treating or reducing the severity of one or more diseases and conditions associated with BTK. In some embodiments, the disease or condition is an autoimmune disease, such as inflammatory bowel disease, arthritis, systemic lupus erythematosus (SLE or lupus), lupus nephritis, vasculitis, idiopathic thrombocytopenic purpura (ITP), rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease, autoimmune thyroiditis, Sjogren's syndrome, multiple sclerosis, systemic sclerosis, Lyme neuroborreliosis, Guillain-Barre syndrome, acute disseminated encephalomyelitis, Addison's disease, ocular cloaca, and the like. The disease or condition is selected from the group consisting of leucine-myoclonus syndrome, ankylosing spondylitis, antiphospholipid syndrome, aplastic anemia, autoimmune hepatitis, autoimmune gastritis, pernicious anemia, celiac disease, Goodpasture's syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary biliary cirrhosis, Reiter's syndrome, Takayasu's arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis, alopecia universalis, Behcet's disease, chronic fatigue, dysautonomia, membranous glomerular nephropathy, endometriosis, interstitial cystitis, pemphigus vulgaris, bullous pemphigoid, neuromyotonia, scleroderma, and vulvodynia. In some embodiments, the disease or condition is systemic lupus erythematosus (SLE or lupus) or lupus nephritis.
[0270] In some embodiments, the disease or condition is a hyperproliferative or immunologically mediated disease, including rejection of transplanted organs or tissues and Acquired Immune Deficiency Syndrome (AIDS, also known as HIV).
[0271] In some embodiments, the present invention provides methods for treating or lessening the severity of one or more diseases and conditions associated with BTK, where the disease or condition is selected from a xenoimmune disease or condition, including, but not limited to, graft versus host disease, transplantation, blood transfusion, anaphylaxis, allergy (e.g., allergy to plant pollen, latex, drugs, food, insect venom, animal hair, animal dander, house dust mites, or cockroach calyx), type I hypersensitivity, allergic conjunctivitis, allergic rhinitis, and atopic dermatitis. In some embodiments, the invention provides a method for treating or lessening the severity of one or more diseases and conditions associated with BTK, wherein the disease or condition is an inflammatory disease, such as, for example, asthma, appendicitis, atopic dermatitis, asthma, allergy, ophthalmitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic graft rejection, colitis, conjunctivitis, Crohn's disease, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, The disease is selected from fasciitis, connective tissue inflammation, gastritis, gastroenteritis, Henoch-Schönlein purpura, hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, ulcerative colitis, uveitis, vaginitis, vasculitis, or vulvitis.
[0272] In some embodiments, the present invention provides a method for treating or reducing the severity of one or more diseases and conditions associated with BTA, wherein the disease or condition is an inflammatory disease, e.g., asthma, appendicitis, atopic dermatitis, asthma, allergy, ophthalmitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic transplant rejection, colitis, conjunctivitis, Crohn's disease, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymis. In one embodiment, the medical condition is selected from the group consisting of inflammatory bowel disease, fasciitis, connective tissue inflammation, gastritis, gastroenteritis, Henoch-Schönlein purpura, hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, pharyngitis, mastitis, meningitis, myelitis, myelitis, myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, ulcerative colitis, uveitis, vaginitis, vasculitis, or vulvitis.
[0273] In some embodiments, the present invention provides methods for treating or lessening the severity of one or more diseases and conditions associated with BTK, including, without limitation, bone and joint diseases, including rheumatoid arthritis, seronegative spondyloarthropathy (including ankylosing spondylitis, psoriatic arthritis, and Reiter's disease), Behcet's disease, Sjogren's syndrome, systemic sclerosis, osteoporosis, bone cancer, and bone metastases.
[0274] In some embodiments, the present invention provides a method for treating or lessening the severity of one or more diseases and conditions associated with BTK, where the disease or condition is selected from a thromboembolic disorder or cardiovascular disorder, e.g., myocardial infarction, angina pectoris, reocclusion after angioplasty, restenosis after angioplasty, reocclusion after aortocoronary bypass surgery, restenosis after aortocoronary bypass surgery, stroke, transient ischemia, peripheral arterial occlusive disorder, pulmonary embolism, or deep vein thrombosis. In some embodiments, the present invention provides an antithrombotic agent, since BTK is also involved in platelet activity.
[0275] In some embodiments, the present invention provides methods for treating or reducing the severity of one or more diseases and conditions associated with BTK, including infectious and non-infectious inflammatory events, and autoimmune and other inflammatory diseases. These autoimmune and inflammatory diseases, disorders, and syndromes include pelvic inflammatory disease (IAD), inflammatory bowel disease (IFD), and other conditions that may be associated with BTK. disease), urethritis, sunburn of the skin, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, gastritis, enteritis, dermatitis, gingivitis, appendicitis, pancreatitis, cholecystitis, agammaglobulinemia, psoriasis, allergies, Crohn's disease, irritable bowel syndrome, ulcerative colitis, Sjogren's disease, tissue graft rejection, hyperacute rejection of transplanted organs, asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome), autoimmune alopecia, pernicious anemia, glomerulonephritis, dermatomyositis, multiple sclerosis, scleroderma, vasculitis, autoimmune hemolysis and thrombocytopenia In some embodiments, the diabetes mellitus is type I diabetes.
[0276] In some embodiments, the present invention provides methods for treating or lessening the severity of one or more diseases and conditions associated with BTK selected from rheumatoid arthritis, multiple sclerosis, B-cell chronic lymphocytic leukemia, acute lymphocytic leukemia, hairy cell leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, bone cancer, bone metastasis, osteoporosis, diabetes (e.g., type I diabetes), irritable bowel syndrome, Crohn's disease, lupus, and kidney transplantation.
[0277] In certain embodiments, the present invention provides a method for the treatment and / or prophylaxis of multiple sclerosis (MS), including relapsing MS (RMS), relapsing-remitting MS (RRMS), progressive MS (PMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), and progressive-relapsing MS (PRMS), comprising administering to a subject a solid form of Compound 1.
[0278] It is another object of the present invention to provide a method for treating diseases caused, mediated, and / or propagated by BTK activity, wherein a solid form of Compound 1, or a pharma- ceutically acceptable salt thereof, is administered to a mammal in need of such treatment. In some embodiments, the present invention provides a method for treating lupus, wherein a solid form of Compound 1, or a pharma- ceutically acceptable salt thereof, is administered to a mammal in need of such treatment. In some embodiments, the compound is administered in an effective amount as defined above. In some embodiments, the treatment is oral administration.
[0279] The method of the present invention can be carried out either in-vitro or in-vivo. The sensitivity of a particular cell to treatment with a compound according to the present invention can be specifically determined by in-vitro testing, whether in a research process or in clinical application. Typically, a culture of the cells is combined with a compound according to the present invention at various concentrations for a period of time sufficient to allow the active agent to inhibit BTK activity, usually between about one hour and one week. In-vitro treatment can be carried out using cultivated cells from a biopsy sample or a cell line.
[0280] The host or patient may belong to any mammalian species, such as a primate species, specifically humans; rodents, including mice, rats and hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are the subject of experimental investigations and provide models for the treatment of human diseases.
[0281] For the identification of signal transduction pathways and for the detection of interactions between various signal transduction pathways, various scientists have developed suitable models or model systems, such as cell culture models and transgenic animal models. For the determination of a certain stage of the signal transduction cascade, interacting compounds can be utilized to modulate the signal. The compounds according to the present invention can also be used as reagents for studying BTK-dependent signal transduction pathways in animal and / or cell culture models or in clinical diseases mentioned in this application.
[0282] Moreover, the following teachings herein regarding the use of solid forms of Compound 1 or pharma- ceutically acceptable salts thereof for the production of medicaments for prophylactic or therapeutic treatment and / or monitoring are believed to be valid and applicable, without limitation, to the use of the compounds for the inhibition of BTK activity.
[0283] The present invention also relates to the use of solid forms of Compound 1 or pharma- ceutically acceptable salts thereof for the prophylactic or therapeutic treatment and / or monitoring of diseases caused, mediated, and / or propagated by BTK activity. Furthermore, the present invention relates to the use of solid forms of Compound 1 or pharma- ceutically acceptable salts thereof for the production of a medicament for the prophylactic or therapeutic treatment and / or monitoring of diseases caused, mediated, and / or propagated by BTK activity. In one embodiment, the present invention provides the use of solid forms of Compound 1 or pharma- ceutically acceptable salts thereof for the production of a medicament for the prophylactic or therapeutic treatment of a BTK-mediated disorder.
[0284] Another object of the present invention is a solid form of Compound 1, or a pharma- ceutically acceptable salt thereof, for use in the prophylactic or therapeutic treatment and / or monitoring of diseases caused, mediated and / or propagated by BTK activity. Another preferred object of the present invention is directed to a solid form of Compound 1, or a pharma- ceutically acceptable salt thereof, for use in the prophylactic or therapeutic treatment and / or monitoring of lupus.
[0285] The solid forms of compound 1 or their pharmaceutically acceptable salts can act as a treatment by being administered once or several times before or after the onset of the disease. The aforementioned compounds and pharmaceuticals of use in relation to the present invention are specifically used for therapeutic treatment. The therapeutically relevant effect is to alleviate to some extent one or more symptoms of the disorder or to restore, partially or completely, one or more physiological or biochemical parameters related to or causing the disease or pathological condition to normal. Monitoring is considered as a kind of treatment, provided that the compound is administered at distinct intervals, for example, to boost the response and completely eliminate the pathogen and / or symptoms of the disease. Either the same compound or different compounds can be applied. The method of the present invention can also be used to reduce the possibility of developing a disorder, or even to prevent the occurrence of a disorder related to BTK activity in advance, or to treat the symptoms that arise and continue to occur.
[0286] In the sense of the present invention, prophylactic treatment is advisable if the subject possesses any prerequisite for the aforementioned physiological or pathological conditions, such as a familial disposition, a genetic defect, or a previously occurring disease.
[0287] The present invention also relates to a medicament comprising at least one solid form of Compound 1 or a pharma- ceutically acceptable salt thereof.
[0288] A "medicine" in the sense of the present invention is any agent in the medical field that comprises one or more compounds of formula (I) or preparations thereof (e.g. pharmaceutical compositions or pharmaceutical formulations) and that can be used in the prophylaxis, treatment, monitoring or aftercare of patients suffering from a disease associated with BTK activity, such that a pathogenic modification of their general condition or of the condition of a specific area of the organism can only become established, at least temporarily.
[0289] In various embodiments, the active ingredient may be administered alone or in combination with other treatments.Synergistic effects may be achieved by using more than one compound in a pharmaceutical composition, i.e., the compound of formula (I) is combined with at least one other agent as an active ingredient, either another compound of formula (I) or a compound of a different structural framework.The active ingredients may be used simultaneously or sequentially.
[0290] Included herein are methods of treatment in which at least one chemical entity provided herein is administered in combination with an anti-inflammatory agent, including, but not limited to, NSAIDs, nonspecific and COX-2 specific cyclooxygenase enzyme inhibitors, gold compounds, corticosteroids, methotrexate, tumor necrosis factor (TNF) antagonists, immunosuppressants, and methotrexate.
[0291] Examples of NSAIDs include, but are not limited to, ibroprofen, flurbiprofen, naproxen and naproxen sodium, diclofenac, diclofenac sodium combined with misoprost, sulindac, oxaprozin, diflunisal, piroxicam, indomethacin, etodolac, fenoprofen calcium, ketoprofen, sodium nabumetone, sulfasalazine, tolmetin sodium, and hydroxychloroquine. Examples of NSAIDs also include COX-2 specific inhibitors such as celecoxib, valdecoxib, lumiracoxib, and / or etoricoxib.
[0292] In some embodiments, the anti-inflammatory agent is a salicylates, including but not limited to acetylsalicylic acid or aspirin, sodium salicylate, and choline and magnesium salicylates.
[0293] The anti-inflammatory agent may also be a corticosteroid, for example, the corticosteroid may be cortisone, dexamethasone, methylprednisolone, prednisolone, prednisolone sodium phosphate, or prednisone.
[0294] In additional embodiments, the anti-inflammatory agent is a gold compound, such as sodium gold thiomalate or auranofin.
[0295] The invention also includes embodiments in which the anti-inflammatory agent is a metabolic inhibitor, such as a dihydrofolate reductase inhibitor, eg, methotrexate, or a dihydroorotate dehydrogenase inhibitor, eg, leflunomide.
[0296] Other embodiments of the invention relate to combinations in which at least one anti-inflammatory compound is an anti-monoclonal antibody (such as eculizumab or pexelizumab), a TNF antagonist such as etanercept, or an anti-TNF alpha monoclonal antibody, infliximab.
[0297] Yet other embodiments of the present invention relate to combinations in immunosuppressant compounds, such as immunosuppressant compounds where at least one active agent is selected from methotrexate, leflunomide, cyclosporine, tacrolimus, azathioprine, and mycophenolate mofetil.
[0298] B cells and B cell precursors that express BTK have been implicated in the pathology of B cell malignancies, including, but not limited to, B cell lymphoma, lymphoma (including Hodgkin's lymphoma and non-Hodgkin's lymphoma), hairy cell lymphoma, multiple myeloma, chronic and acute myeloid leukemia, and chronic and acute lymphocytic leukemia.
[0299] BTK has been shown to be an inhibitor of the Fas / APO-1 (CD-95) death-inducing signaling complex (DISC) in B-lineage lymphoid cells. The fate of leukemia / lymphoma cells may reside in the balance between the opposing proapoptotic effects of caspases activated by the DISC and upstream antiapoptotic regulatory mechanisms involving BTK and / or its substrates (Vassilev et al., J. Biol. Chem. 1998, 274, 1646-1656).
[0300] It has also been discovered that BTK inhibitors are useful as chemosensitizing agents and thus are useful in combination with other chemotherapeutic agents, particularly drugs that induce apoptosis. Examples of other chemotherapeutic agents that can be used in combination with chemosensitizing BTK inhibitors include topoisomerase I inhibitors (camptothecin or topotecan), topoisomerase II inhibitors (e.g., daunomycin and etoposide), alkylating agents (e.g., cyclophosphamide, melphalan, and BCNU), tubulin directed agents (e.g., taxol and vinblastine), and biological agents (e.g., antibodies such as anti-CD20 antibodies, IDEC 8, immunotoxins, and cytokines).
[0301] The disclosed compounds of formula I can be administered in combination with other known therapeutic agents, including anti-cancer agents. As used herein, the term "anti-cancer agent" refers to any agent administered to a patient with cancer for the purpose of treating the cancer.
[0302] The anti-cancer treatment defined above may be applied as a monotherapy or may involve, in addition to the compound of formula I disclosed herein, conventional surgery or radiation therapy or medicinal therapy. Such medicinal therapy (e.g. chemotherapy or targeted therapy) may include one or more of the following antitumor agents, preferably one of them: Alkylating agents:Altretamine, bendamustine, busulfan, carmustine, chlorambucil, chlormethine, cyclophosphamide, dacarbazine, ifosfamide, improsulfan, tosilate, lomustine, melphalan, mitobronitol, mitolactol, nimustine, ranimustine, temozolomide, thiotepa, treosulfan, mechlorethamine, carboquone; apaziquone, fotemustine, glufosfamide, palifosfamide, pipobroman, trofosfamide, uramustine, TH-302 4 , VAL-083 4 etc; Platinum compounds: Carboplatin, cisplatin, eptaplatin, miriplatin hydrate, oxaliplatin, lobaplatin, nedaplatin, picoplatin, satraplatin; lobaplatin, nedaplatin, picoplatin, satraplatin, etc.; DNA modifying agents: Amrubicin, bisantrene, decitabine, mitoxantrone, procarbazine, trabectedin, clofarabine; amsacrine, brostallicin, pixantrone, laromustine 1,3 etc; Topoisomerase inhibitors: Etoposide, irinotecan, razoxane, sobuzoxane, teniposide, topotecan; amonafide, belotecan, elliptinium acetate, borreloxine, etc.; Microtubule modifier: Cabazitaxel, docetaxel, eribulin, ixabepilone, paclitaxel, vinplastine, vincristine, vinorelbine, vindesine, vinflunine; fosbretabine, tesetaxel, etc.; Antimetabolites: Asparaginase 3 , azacitidine, levofolinate calcium, capecitabine, cladribine, cytarabine, enocitabine, floxuridine, fludarabine, fluorouracil, gemcitabine, mercaptopurine, methotrexate, nelarabine, pemetrexed, pralatrexate, azathioprine, thioguanine, carmofur; doxifluridine, elacitabine, raltitrexed, cepacitabine, tegafur2,3 , trimethotrexate, etc.; Anticancer antibiotics: Bleomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, levamisole, miltefosine, mitomycin C, romidepsin, streptozocin, valrubicin, zinostatin, zorubicin, daunorubicin, plicamycin; aclarubicin, peplomycin, pirarubicin, etc.; Hormones / antagonists: Abarelix, abiraterone, bicalutamide, buserelin, calcineurin, chlorotonianisene, degarelix, dexamethasone, estradiol, flutocortolone, fluoxymesterone, flutamide, fulvestrant, goserelin, histrelin, leuprorelin, megestrol, mitotane, nafarelin, nandrolone, nilutamide, octreotide, prednisolone, raloxifene, tamoxifen, thyrotropin alfa, toremifene, trilostane, triptorelin, diethylstilbestrol; acolbifene, danazol, deslorelin, epithiostanol, orteronel, enzalutamide 1,3 etc; Aromatase inhibitors: Aminoglutethimide, anastrozole, exemestane, fadrozole, letrozole, testolactone; formestane, etc.; Small Molecule Kinase Inhibitors: Crizotinib, dasatinib, erlotinib, imatinib, lapatinib, nilotinib, pazopanib, regorafenib, ruxolitinib, sorafenib, sunitinib, vandetanib, vemurafenib, bosutinib, gefitinib, axitinib; afatinib, alisertib, dabrafenib, dacomitinib, dinaciclib, dovitinib, ectocalcitab ... Inzastaurin, nintedanib, lenvatinib, linifanib, linsitinib, masitinib, midostaurin, motesanib, neratinib, orantinib, perifosine, ponatinib, radotinib, rigosertib, tipifanib, tivantinib, tivozanib, trametinib, pimasertib, brivanib alaninate, cediranib, apatinib 4 , Cabozantinib S-malate 1,3 , ibrutinib 1,3 , Icotinib4 , buparlisib 2 , cipatinib 4 , cobimetinib 1,3 , idelalisiv 1,3 , fedratinib 1 , XL-647 4 etc; Photosensitizers: Methoxsalen 3 ;Polyfimer sodium, talaporfin, temoporfin, etc.; antibody: Alemtuzumab, besilesomab, brentuximab vedotin, cetuximab, denosumab, ipilimumab, ofatumumab, panitumumab, rituximab, tositumomab, trastuzumab, bevacizumab, pertuzumab 2,3 ; Catumaxomab, elotuzumab, epratuzumab, farletuzumab, mogamulizumab, necitumumab, nimotuzumab, obinutuzumab, ocaratuzumab, oregovomab, ramucirumab, rilotumumab, siltuximab, tocilizumab, zalutumumab, zanolimumab, matuzumab, dalotuzumab 1,2,3 , Onartuzumab 1,3 , racotumomab 1 , tabalumab 1,3 , EMD-525797 4 , nivolumab 1,3 etc; Cytokines: Aldesleukin, interferon alpha 2 , interferon alpha 2a 3 , interferon alpha 2b 2,3 ; Celmoleukin, tasonermin, teseleukin, operelvekin 1,3 , recombinant interferon beta-1a 4 etc; Drug conjugates:Denileukin diftitox, ibritumomab tiuxetan, iobenguane I123, prednimustine, trastuzumab emtansine, estramustine, gemtuzumab, ozogamicin, aflibercept; syntredekin besudotox, edotreotide, inotuzumab ozogamicin, naptumomab estafenatox, oportuzumab monatox, technetium (99mTc) arcitumomab 1,3 , Vintafolid 1,3 etc; vaccine: Sipuleucel 3 ; Bitespen 3 , emepepimut-S 3 , OncoVAX 4 , Lindopepimut 3 , troVax 4 , MGN-1601 4 , MGN-1703 4 etc.; and others: Alitretinoin, bexarotene, bortezomib, everolimus, ibandronate, imiquimod, lenalidomide, lentinan, metyrosine, mifamurtide, pamidronate, pegaspargase, pentostatin, sipuleucel 3 , sizofiran, tamibarotene, temsirolimus, thalidomide, tretinoin, vismodegib, zoledronic acid, vorinostat; celecoxib, cilengitide, entinostat, etanidazole, ganetespib, idronoxyl, iniparib, ixazomib, lonidamine, nimorazole, parabinostat, peretinoin, plitidepsin, pomalidomide, procodazol, ridaforolimus, tasquinimod, telotristat, simalfasin, tirapazamine, tosedostat, travedersen, ubenimex, valspodar, and gendicine 4 , Picibanil 4 , Leolysin 4 , Retaspimycin hydrochloride 1,3 , Trebananib 2,3 , bilirudin 4 , Carfilzomib 1,3, endostatin 4 , Immucothel 4 , Belinostat 3 , MGN-1703 4 . ( 1 Prop. INN (Proposed International Nonproprietary Name); 2 Rec. INN (Recommended International Nonproprietary Name); 3 USAN (United States Adopted Name); 4 No INN).
[0303] In another aspect, the present invention provides a kit consisting of separate packs of an effective amount of the compounds according to the present invention and / or their pharma- ceutically acceptable salts, derivatives, solvates and stereoisomers (including mixtures thereof in any ratio), and optionally an effective amount of a further active ingredient.The kit comprises suitable containers such as boxes, individual bottles, bags or ampoules.The kit may, for example, comprise separate ampoules, each of which contains an effective amount of the compounds according to the present invention and / or their pharma-ceutically acceptable salts, derivatives, solvates and stereoisomers (including mixtures thereof in any ratio), and optionally an effective amount of a further active ingredient, in dissolved or lyophilized form.
[0304] As used herein, the terms "treatment", "treat" and "treating" refer to reversing, alleviating, delaying, or inhibiting the progression of a disease or disorder as described herein, or one or more symptoms thereof. In some embodiments, treatment is administered after one or more symptoms have developed. In other embodiments, treatment is administered in the absence of symptoms. For example, treatment is administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of the condition and / or in light of genetic or other susceptibility factors). Treatment also continues after symptoms have resolved, e.g., to prevent or delay their recurrence.
[0305] The compounds and compositions according to the method of the present invention are administered in any amount and using any route of administration effective for treating or reducing the severity of the disorders provided above. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the specific agent, its mode of administration, and the like. The compounds of the present invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. However, it will be understood that the total daily usage of the compounds and compositions of the present invention will be determined by the attending physician within the scope of sound medical judgment. The specific dosage level effective for any particular patient or organism will depend on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the particular compound employed; the particular compound employed; the patient's age, weight, general health, sex, and diet; the time of administration, route of administration, and rate of excretion of the particular compound employed; the duration of treatment; drugs used in combination or concomitantly with the particular compound employed, and similar factors well known in the medical arts.
[0306] The pharma- ceutically acceptable compositions of the present invention may be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (such as by powders, ointments, or drops), buccally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In some embodiments, the compounds of the present invention are administered orally or parenterally at dosage levels of about 0.01 mg / kg body weight (of the subject) to about 100 mg / kg per day, preferably from about 1 mg / kg body weight (of the subject) to about 50 mg / kg, one or more times per day to obtain the desired therapeutic effect.
[0307] Liquid dosage forms for oral administration include, but are not limited to, pharma- ceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.In addition to active compounds, liquid dosage forms optionally contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof.Besides inert diluents, oral compositions also contain adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavorings and colorings.
[0308] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, are formulated according to known art using suitable dispersing or wetting agents and suspending agents.Sterile injectable preparations are also sterile injectable solutions, suspensions or emulsions in non-toxic parenterally acceptable diluents or solvents, for example, as solutions in 1,3-butanediol.Among acceptable vehicles and solvents that may be employed are water, Ringer's solution, USP and isotonic sodium chloride solution.In addition, sterile fixed oils are conventionally employed as solvents or suspending media.For this purpose, any bland fixed oil that may be employed includes synthetic mono- or di-glycerides.In addition, fatty acids such as oleic acid are used in injectable preparations.
[0309] The injectable preparations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0310] In order to prolong the effect of the compounds of the present invention, it is often desirable to delay the absorption of the compound from subcutaneous or intramuscular injection. This is accomplished by using a liquid suspension of poorly soluble crystalline or amorphous material. The rate of absorption of the compound then depends on its dissolution rate, which in turn may depend on crystal size and crystalline form. Alternatively, delayed absorption of parenterally administered compound forms can also be achieved by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsulated matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of compound to polymer and the nature of the specific polymer employed, the compound release rate can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Injectable depot formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with living tissue.
[0311] Compositions for rectal or vaginal administration are preferably suppositories which may be prepared by mixing the compound of the present invention with a suitable non-irritating excipient or carrier, such as cocoa butter, polyethylene glycol, and the like, or a suppository wax which is solid at ambient temperature but liquid at body temperature and which melts in the rectum or vaginal cavity to release the active compound.
[0312] The solid dosage form for oral administration includes capsules, tablets, pills, powders, and granules.In such solid dosage forms, the active compound is mixed with at least one pharma- ceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate, and / or a) filler or extender, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid, b) binder, such as carboxymethylcellulose, alginic acid, gelatin, polyvinylpyrrolidinone, sucrose, and gum acacia, c) humectant, such as glycerol, d) agar, calcium carbonate, potato or tapioca starch, alginic acid, The pharmaceutical composition may be mixed with disintegrating agents such as certain silicates and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form also optionally comprises buffering agents.
[0313] Solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar and high molecular weight polyethylene glycols. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulation art. They can also optionally contain opacifying agents and be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar and high molecular weight polyethylene glycols.
[0314] The active compound may also be in microencapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules may be prepared with coatings and shells, such as enteric coatings, release controlling coatings, and other coatings well known in the pharmaceutical formulation art. In such solid dosage forms, the active compound may be admixed with at least one inert diluent, such as sucrose, lactose, or starch. Conventional dosage forms also contain additional substances other than inert diluents, for example, tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets, and pills, the dosage forms also optionally contain buffering agents. They may optionally contain opacifying agents and may also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that may be used include polymeric substances and polymeric waxes.
[0315] Dosage forms for topical or transdermal administration of the compounds of the present invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is mixed under sterile conditions with a pharma- ceutically acceptable carrier and any necessary preservatives or required buffers. Ophthalmic formulations, ear drops, and eye drops are also contemplated as being within the scope of the present invention. In addition, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of the compound to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate-controlling membrane or dispersing the compound in a polymer matrix or gel.
[0316] According to one aspect, the present invention relates to a method of inhibiting BTK activity in a biological sample, said method comprising the step of contacting said biological sample with a compound of the present invention or a composition comprising said compound.
[0317] According to another aspect, the present invention relates to a method of actively inhibiting BTK, or a mutant thereof, activity in a biological sample, said method comprising the step of contacting said biological sample with a compound of the present invention or a composition comprising said compound.
[0318] The compounds of the present invention are useful in vitro as unique tools for understanding the biological role of BTK, including the evaluation of the numerous factors believed to affect and be affected by BTK production and BTK interactions. The compounds are also useful for the development of other compounds that interact with BTK, since they provide important structure-activity relationship (SAR) information that facilitates their development. Compounds of the present invention that bind to BTK can be used as reagents for detecting BTK from live cells, fixed cells, biological fluids, tissue homogenates, purified natural biological materials, and the like. For example, by labeling such compounds, cells expressing BTK can be identified. In addition, based on their ability to bind to BTK, the compounds of the present invention can be used in enzyme purification, such as in-situ staining, FACS (fluorescence activated cell sorting), sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), ELISA (enzyme-linked immunosorbent assay), or in purifying cells expressing BTK inside permeabilized cells. The compounds of the invention may also be utilized as commercial research reagents for a variety of medical research and diagnostic uses, including, but not limited to, use as calibration standards to quantify the activity of candidate BTK inhibitors in various functional assays; use as blocking agents in random screening of compounds, i.e., searching for new families of BTK ligands, where the compounds may be used to block the recovery of the presently claimed BTK compounds; use in co-crystallization with the BTK enzyme, i.e., the compounds of the invention will form crystals of compounds bound to BTK, allowing the determination of the enzyme / compound structure by X-ray crystallography; other research and diagnostic applications, where BTK is preferably activated or such activation is conveniently calibrated against known quantities of, e.g., BTK inhibitors; use in assays as probes to determine expression of BTK in cells; and developing assays to detect compounds that bind to the same site as the BTK-binding ligands.
[0319] The compounds of the present invention can be applied either by themselves and / or in combination with physical measurements for the diagnosis of the efficacy of treatment. Pharmaceutical compositions containing the compounds and their use to treat BTK-mediated diseases are promising new approaches to broad-spectrum treatments that cause direct and immediate improvement of the state of health, whether in humans or animals. The new orally bioavailable and active chemical entities of the present invention improve convenience for patients and compliance for physicians.
[0320] The compounds of formula (I), their salts, isomers, tautomers, enantiomeric forms, diastereomers, racemates, derivatives, prodrugs and / or metabolites are characterized by high specificity and stability, low production costs and convenient handling. These features form the basis for a reproducible action (which includes the lack of cross-reactivity) and for a reliable and safe interaction with target structures.
[0321] The term "biological sample" as used herein includes, without limitation, cell cultures or extracts thereof; biopsies obtained from mammals or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other bodily fluids, or extracts thereof.
[0322] Modulation of BTK, or a mutant thereof, activity in a biological sample is useful for a variety of purposes known to those of skill in the art, including, but not limited to, blood transfusions, organ transplants, biological specimen storage, and biological assays.
[0323] Example As depicted in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures: While the general methods depict the synthesis of certain compounds of the invention, it will be understood that the following general methods, as well as other methods known to those of skill in the art, may be applied to all compounds as described herein, and each subclass and species of these compounds.
[0324] The symbols and conventions used in the described processes, schemes, and examples which follow are consistent with those used in the contemporary scientific literature, e.g., the Journal of the American Chemical Society or the Journal of Biological Chemistry.
[0325] All forms were characterized according to standard methods found, for example, in Rolf Hilfiker, 'Polymorphism in the Pharmaceutical Industry', Wiley-VCH. Weinheim 2006 (Chapter 6:X-Ray Diffraction, Chapter 6:Vibrational Spectroscopy, Chapter 3:Thermal Analysis, Chapter 9:Water Vapour Sorption, and references therein); and HG Brittain, 'Polymorphism in Pharmaceutical Solids, Vol. 95, Marcel Dekker Inc., New York 1999 (Chapter 6 and references therein).
[0326] All temperatures are expressed in °C (degrees Celsius) unless otherwise indicated. All reactions were carried out at room temperature unless otherwise noted. All compounds of the present invention were synthesized by processes developed by the inventors.
[0327] 1H-NMR spectra were recorded on a Bruker Avance III 400 MHz. Chemical shifts are expressed in parts per million (ppm, δ units). Coupling constants are in Hertz (Hz). Splitting patterns describe the apparent multiplicity and are designated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), or br (broad).
[0328] Mass spectra were obtained on an Agilent 1200 Series mass spectrometer from Agilent technologies using either atmospheric pressure chemical ionization (APCI) or electrospray ionization (ESI). Column: XBridge C8, 3.5 μm, 4.6×50 mm; Solvent A: water + 0.1% TFA; Solvent B: CAN; Flow: 2 ml / min; Gradient: 0 min: 5% B, 8 min: 100% B, 8.1 min: 100% B, 8.5 min: 5% B, 10 min: 5% B.
[0329] HPLC data was obtained indexed on an Agilent 1100 series HPLC from Agilent technologies using an XBridge column (C8, 3.5 μm, 4.6×50 mm). Solvent A: water + 0.1% TFA; Solvent B: ACN; Flow: 2 ml / min; Gradient: 0 min: 5% B, 8 min: 100% B, 8.1 min: 100% B, 8.5 min: 5% B, 10 min: 5% B.
[0330] Microwave reactions were carried out using a Biotage Initiator Microwave Synthesizer using standard protocols known in the art.
[0331] Some abbreviations that may appear in this application are as follows: [Table 17]
[0332] The compound numbers utilized in the examples below correspond to the compound numbers above. Example 1: Freeze-drying experiments from 0.1% TFA-HO / ACN mixtures (following variations as described in method S4A in WO2012 / 170976)
[0333] a) Lyophilization from 0.1% TFA-H2O:ACN 90:10 (v:v):
[0334] Approximately 200 mg of purified free base was dissolved in 50 mL of a mixture of 0.1% TFA-H2O:ACN 90:10 (v:v) at RT (approximately 22°C). The material was almost completely dissolved. Filtration through a 0.45 μm syringe filter was performed to obtain a clear solution. The solution was flash frozen in liquid nitrogen in a 100 mL round-bottom flask and the frozen sample was attached to a lyophilisator (Steris, Lyovac GT2) operating at approximately 0.8 mbar. After one day, the white solid residue was collected.
[0335] NMR: Stoichiometry API:TFA approximately 1:1.1
[0336] 1 H NMR (400 MHz, DMSO-d6) d 8.36 (s, 1H), 7.48 - 7.41 (m, 2H), 7.32 - 7.25 (m, 2H), 7.23 - 7.07 (m, 7H), 6.87 (t, J = 6.5 Hz, 1H), 6.80 (dd, J = 16.7, 10.5 Hz, 1H), 6.09 (dd, J = 16.8, 2.4 Hz, 1H), 5.67 (dd, J = 10.4, 2.4 Hz, 1H), 4.28 - 4.18 (m, 1H), 3.97 - 3.87 (m, 1H), 3.64 (dd, J = 20.6, 6.5 Hz, 2H), 3.24 (t, J = 12.7 Hz, 1H), 2.88 (t, J = 12.6 Hz, 1H), 1.78 - 1.68 (m, 2H), 1.68 - 1.44 (m, 2H)
[0337] b) Lyophilization from 0.1% TFA-H2O:ACN 50:50 (v:v):
[0338] Approximately 200 mg of purified free base was dissolved in 15 mL of a mixture of 0.1% TFA-H2O:ACN 50:50 (v:v) at RT (approximately 22°C). The material was almost completely dissolved. Filtration through a 0.45 μm syringe filter was performed to obtain a clear solution. The solution was flash frozen in liquid nitrogen in a 100 mL round-bottom flask and the frozen sample was attached to a freeze dryer (Steris, Lyovac GT2) operating at approximately 0.8 mbar. After one day, the white solid residue was collected.
[0339] NMR: Stoichiometry API:TFA approximately 1:0.3
[0340] 1 H NMR (400 MHz, DMSO-d6) d 8.06 (s, 1H), 7.46 - 7.39 (m, 2H), 7.27 - 7.22 (m, 2H), 7.21 - 7.15 (m, 1H), 7.15 - 7.09 (m, 4H), 6.80 (dd, J = 16.7, 10.4 Hz, 1H), 6.09 (dd, J = 16.7, 2.4 Hz, 1H), 6.01 - 5.90 (m, 2H), 5.71 - 5.62 (m, 1H), 5.66 (dd, J = 10.5, 2.4 Hz, 1H), 4.25 - 4.14 (m, 1H), 3.95 - 3.85 (m, 1H), 3.60 (dd, J = 20.8, 6.4 Hz, 2H), 2.94 - 2.85 (m, 1H), 1.76 - 1.66 (m, 2H), 1.66 - 1.45 (m, 2H)
[0341] c) Lyophilization from 0.1% TFA-H2O:ACN 10:90 (v:v)
[0342] Approximately 200 mg of purified free base was dissolved in 8 mL of a mixture of 0.1% TFA-H2O:ACN 10:90 (v:v) at RT (approximately 22°C). The material was almost completely dissolved. Filtration through a 0.45 μm syringe filter was performed to obtain a clear solution. The solution was flash frozen in liquid nitrogen in a 100 mL round-bottom flask and the frozen sample was attached to a freeze dryer (Steris, Lyovac GT2) operating at approximately 0.8 mbar. After one day, the white solid residue was collected.
[0343] NMR: Stoichiometry API:TFA approximately 1:0.02
[0344] 1 H NMR (400 MHz, DMSO-d6) d 7.96 (s, 1H), 7.46 - 7.38 (m, 2H), 7.27 - 7.21 (m, 2H), 7.20 - 7.14 (m, 1H), 7.14 - 7.08 (m, 4H), 6.80 (dd, J = 16.7, 10.5 Hz, 1H), 6.09 (dd, J = 16.6, 2.4 Hz, 1H), 5.65 (dd, J = 10.5, 2.4 Hz, 1H), 5.60 - 5.51 (m, 2H), 5.20 (t, J = 6.4 Hz, 1H), 4.24 - 4.13 (m, 1H), 3.95 - 3.85 (m, 1H), 3.58 (dd, J = 20.9, 6.4 Hz, 2H), 3.28 - 3.19 (m, 1H), 2.90 (t, J = 12.7 Hz, 1H), 1.76 - 1.66 (m, 2H), 1.65 - 1.45 (m, 2H) Example 2: Crystallization process of the free base to obtain pure form A1
[0345] Small scale: Crystallization from several solvents by isothermal solvent evaporation
[0346] Approximately 10 mg of free base was dispersed or dissolved in 500 µL to 4 mL (depending on solubility) of several solvents at RT or 50 °C. All suspensions / solutions were filtered using a 0.2 µm syringe filter. The vials with the clear filtrate were left uncovered in a tempered aluminum rack for solvent evaporation until a dry solid residue was obtained. Form A1 was obtained in the following solvents: 25° C.: ethanol, 1-propanol, 2-propanol, 2-butanol, acetone, methyl ethyl ketone, methyl isobutyl ketone, ethyl acetate, 1,4-dioxane, diethyl ether, methyl tert butyl ether, tetrahydrofuran, acetonitrile, dichloromethane, chloroform, toluene, pyridine; 50° C.: ethanol, 1-propanol, 1-butanol, iso-butanol, methyl ethyl ketone, methyl isobutyl ketone, ethyl acetate, 1,4-dioxane, diethyl ether, methyl tert butyl ether, tetrahydrofuran, acetonitrile, dichloromethane, chloroform, N,N-dimethylformamide, toluene, ortho-xylene, para-xylene, pyridine.
[0347] b) Small scale: cooling crystallization from several solvents
[0348] Approximately 14 mg of the free base was dispersed or dissolved in 200 μL-1 mL (depending on solubility) of several solvents at RT or 50° C. All suspensions / solutions were filtered using a 0.2 μm syringe filter. The vials with the clear filtrate were capped and left in a tempered aluminum rack for solvent evaporation until a dry solid residue was obtained and cooled to 5° C. at 0.1 K / min. The resulting solid was subjected to solid- / liquid separation by centrifugation using PE centrifuge vials. Form A1 was obtained in the following solvents:
[0349] Ethanol, 2-propanol, acetone, methyl isobutyl ketone, ethyl acetate, acetonitrile, toluene.
[0350] c) Large scale: combination of evaporation and cooling crystallization
[0351] A 65 L enamel reactor was inerted with nitrogen. Using a feed vessel, 25 L of ethanol absolute was charged to the reactor. Stirring, condenser 0° C. and jacket temperature 30° C. were started. Then the product was charged (3980 g of free base in several batches). The jacket temperature was increased to 95° C. After 30 min, the reaction temperature was 78° C. (reflux conditions) and a cloudy solution was formed. The hot mixture was filtered on a pressure filter and rinsed with 2 L of ethanol. A small amount of brown residue was detected in the vessel and on the filter. The filtrate was transferred into a rotary evaporator. Approximately 13 L of ethanol was distilled off until crystallization started. The mixture was charged into a steel pot and stirred under ice cooling for 2 h while a precipitate was formed. The precipitate was filtered under suction and rinsed with 1 L of ethanol. It was then dried in a vacuum dryer at 50° C. and 30 mbar for 2 days. The product was milled in a comil U5 (mesh size 1 mm).
[0352] 1 H NMR (400 MHz, DMSO-d6) d 7.96 (s, 1H), 7.46 - 7.39 (m, 2H), 7.27 - 7.21 (m, 2H), 7.20 - 7.14 (m, 1H), 7.14 - 7.09 (m, 4H), 6.79 (dd, J = 16.7, 10.5 Hz, 1H), 6.09 (dd, J = 16.7, 2.4 Hz, 1H), 5.65 (dd, J = 10.5, 2.4 Hz, 1H), 5.62 - 5.50 (m, 2H), 5.20 (t, J = 6.4 Hz, 1H), 4.24 - 4.13 (m, 1H), 3.95 - 3.84 (m, 1H), 3.59 (dd, J = 20.9, 6.4 Hz, 2H), 3.24 (t, J = 12.9 Hz, 1H), 2.91 (t, J = 12.2 Hz, 1H), 1.77 - 1.65 (m, 2H), 1.67 - 1.45 (m, 2H). Example 3: Crystallization process of the free base to obtain pure form A2
[0353] a) Small scale: Cooling crystallization from 2-propanol
[0354] Approximately 14 mg of the free base was completely dissolved in 200 μL to 1 mL of 2-propanol. The solution was filtered using a 0.2 μm syringe filter. The vial with the clear filtrate was capped and placed in a tempered aluminum rack and cooled to 5° C. at 0.1 K / min. The resulting solid was subjected to solid-liquid separation by centrifugation using PE centrifuge vials.
[0355] b) Small scale: Slurry transformation form A1 in ethanol
[0356] About 2.5 g of free base Form A1 and 25 mL of ethanol were added to a 50 mL Erlenmeyer flask. The resulting suspension was heated to 50° C. and stirred for about 3 h. About 50 mg of seeds of Form A2 were added to the suspension. In process control, after approximately 20 h by PXRD (IPC1) showed Form A1. An additional amount of about 100 mg of seeds of Form A2 was added to the suspension. A second IPC after 30 h of stirring at 50° C. still showed Form A1. After another 10 h of stirring, the material was completely converted to Form A2 (IPC3). The ethanol was evaporated to dryness on a rotary evaporator under vacuum. The material was finally dried at 80° C. in a dry nitrogen flow.
[0357] c) Large scale: Slurry transformation form A1 in ethanol
[0358] Several batches of drug substance 3.2 kg and 9 L of ethanol anhydrous GR for analysis were added to the reaction mixture of compound 1 and placed in a 25 L enamel reactor (25 L enamel reactor (POS1065)) resulting in a white suspension. A sample was taken (IPC1, 0 h) and PXRD quantification showed a mixture of 13% form A1 and 87% form A2. The suspension was heated to 35° C. (reactor) and stirred overnight. A sample was taken (IPC2, 18 h) and PXRD quantification showed a mixture of 11% form A1 and 89% form A2. Tempering was stopped and the mixture was cooled slowly to room temperature. 30 g of form A2 was powdered in a mortar and added stepwise within 10 min at 28° C. (reactor). The mixture was stirred overnight at room temperature. A sample was taken (IPC3, 41 h) and PXRD quantification showed a mixture of 11% form A1 and 89% form A2. 4x5g of Form A2 were powdered in a mortar and added within 4h at 25°C (reactor). The suspension was heated to 35°C (reactor) and stirred at this temperature over the weekend. A sample was taken (IPC4, 113h) and PXRD quantification showed a mixture of 10% Form A1 and 90% Form A2. After 5h, tempering was stopped. 3x8g of Form A2 were powdered in a mortar and added within 3h at 33-35°C (reactor). The mixture was stirred overnight at 25°C. A sample was taken (IPC5, 137h) and PXRD quantification showed a mixture of 7% Form A1 and 93% Form A2. The mixture was heated to 35°C (reactor). 3x8g of Form A2 were powdered in a mortar and added within 3h at 33-35°C (reactor). Tempering was stopped and the mixture was cooled slowly to room temperature. The mixture was stirred overnight at 25°C (reactor). A sample was taken (IPC5, 161h) and PXRD quantification showed 100% A2. The suspension was heated to 35°C and then tempering was stopped. 3x8g of Form A2 were powdered in a mortar and added within 3h at 33-35°C (reactor). The suspension was cooled slowly to room temperature and stirred overnight. The solvent was removed by distillation in a rotary evaporator (Buechi R220 EX). The concentrated suspension was stored overnight at room temperature. The suspension was filtered under suction.The cake was dried at 50° C. over the weekend at 20 mbar to constant weight and milled using a comil U5 (mesh size 1 mm).
[0359] 1 H NMR (500 MHz, DMSO-d6) d 8.32 (s, 1H), 7.47 - 7.42 (m, 2H), 7.30 - 7.26 (m, 2H), 7.22 - 7.18 (m, 1H), 7.17 - 7.11 (m, 4H), 6.96 - 6.85 (m, 2H), 6.83 - 6.76 (m, 2H), 6.09 (dd, J = 16.7, 2.4 Hz, 1H), 5.66 (dd, J = 10.4, 2.4 Hz, 1H), 4.27 - 4.18 (m, 1H), 3.96 - 3.87 (m, 1H), 3.69 - 3.58 (m, 2H), 3.24 (t, J = 12.8 Hz, 1H), 2.88 (t, J = 12.5 Hz, 1H), 1.78 - 1.68 (m, 2H), 1.67 - 1.46 (m, 2H).
[0360] d) Small scale: Cooling crystallization in methanol by seeding with Form A2
[0361] 30.0 g of drug substance and 120 g of methanol were added to a 250 mL jacketed reactor. The suspension was heated to 65° C. After about 45 min at reflux conditions, a clear yellowish solution was obtained. The jacket temperature was subsequently cooled to 58° C. During cooling, 300 mg of seed crystals of Form A2 (previously powdered in a porcelain mortar) were added to the solution at 59° C. The resulting suspension was further cooled to −28° C. with a cooling rate of −0.23 K / min and finally filtered under vacuum using a funnel filter. The isolated filter cake was washed twice with pre-chilled methanol (at −30° C.) and dried under vacuum at 40° C. for 16 h to obtain 27.3 g of pure crystals of Form A2 (90% yield).
[0362] e) Small scale: Cooling crystallization in ethanol by seeding with Form A2
[0363] 5.0 g of drug substance and 66.4 g of methanol were added to a 250 mL jacketed reactor. The suspension was heated and dissolved at 76° C. to form a clear, slightly yellowish solution. The jacket temperature was subsequently cooled to 58° C. 50 mg of seed crystals of Form A2 (previously powdered in a porcelain mortar) were added to the solution at 58° C. and the resulting suspension was further cooled to −30° C. at a cooling rate of −0.62 K / min. At the final temperature, the suspension was stirred for an additional 22 h (overnight) and finally filtered under vacuum using a funnel filter. The isolated filter cake was washed twice with pre-cooled ethanol (at −30° C.) and dried under vacuum (<10 mbar) at 40° C. for 24 h to give 4.17 g of pure crystals of Form A2 (83% yield).
[0364] f) Large scale: Cooling crystallization in methanol by seeding with Form A2
[0365] 82 L of methanol (7 volumes) was charged to a 250 L reactor and warmed to an external temperature of 70° C. 11.72 g of drug substance was slowly charged to the pre-warmed (reflux) methanol. In roughly 15 minutes the solids were completely dissolved. The hot solution was filtered through a 0.45 μm cartridge. The filtrate was charged to the washed reactor, pre-warmed at 70° C. A temperature ramp was started: +70° C. to −20° C. external temperature in 90 minutes. When the internal temperature reached 50° C., seeding crystals were added (1% wt / wt with respect to crude API). When the external temperature reached −20° C., the mixture was stirred for 30 minutes, then the solids were isolated by filtration, the cake was washed with MeOH, and dried at 50° C. for 12 hours.
[0366] 1H NMR (500 MHz, DMSO-d6) d 7.96 (s, 1H), 7.45 - 7.39 (m, 2H), 7.26 - 7.21 (m, 2H), 7.19 - 7.15 (m, 1H), 7.14 - 7.09 (m, 4H), 6.79 (dd, J = 16.7, 10.5 Hz, 1H), 6.09 (dd, J = 16.7, 2.4 Hz, 1H), 5.65 (dd, J = 10.5, 2.4 Hz, 1H), 5.61 - 5.50 (m, 2H), 5.19 (t, J = 6.4 Hz, 1H), 4.23 - 4.13 (m, 1H), 3.94 - 3.85 (m, 1H), 3.59 (dd, J = 21.1, 6.7 Hz, 2H), 3.24 (t, J = 12.9 Hz, 1H), 2.90 (t, J = 12.3 Hz, 1H), 1.77 - 1.67 (m, 2H), 1.67 - 1.47 (m, 2H).
[0367] g) Kilo-lab: Cool crystallization in methanol without seeding to form A2
[0368] 2300 ml of methanol (6.5 Vol) was charged to an oil jacketed reactor and warmed to ET=70°C. 353.2 g of crude drug substance was slowly charged to the pre-warmed methanol. When the IT reached 58°C, the mixture was still a cloudy solution with undissolved material present. An additional 180 ml (0.5 Vol) of methanol was added and the ET increased to 75°C (IT=reflux at 62°C). In roughly 30 minutes the solids were completely dissolved and the hot solution was filtered on a 2.5 μm paper filter (Whatman 42). The filtrate was charged back into the washed reactor pre-warmed at 70°C. While under suction filtration some product precipitated (cloudy solution appeared) so it was necessary to increase the ET to 75°C to obtain a clear solution. The ET was then lowered to 70°C and a temperature ramp was started: +70°C to -20°C ET in 90 minutes. Example 4: Preparation process for the first step of salt screening
[0369] The first step of the salt screen was carried out using sulfuric acid, phosphoric acid, toluenesulfonic acid and succinic acid.
[0370] Cooling crystallization was started using a 1:1 (base:acid) stoichiometric combination of 2-propanol, toluene and THF / water (0.5:1; v:v). Approximately 20 mg of API was dissolved at high temperature and the acid was dosed to the solution in the respective amount. Solid acid was weighed and added as a solid into the API solution, and liquid acid was dissolved in the respective solvent and added to the API solution by pipette. In no case could spontaneous salt precipitation be observed after dosing of the acid. The solution was then cooled to 5° C. at a slow cooling rate, e.g. 1 K / min (experiment with 2-PrOH, proceeded with 3x cycles of heating→cooling). In case no crystallization occurred, the vial was left in the refrigerator for further days. Evaporative crystallization was performed from acetone at rt.
[0371] Cooling crystallization of both amorphous solid residues, without any solid residue, gave parent form A1. Evaporative crystallization in acetone gave only amorphous residues. These residues were further processed by dissolving in ethanol and by performing vapor diffusion experiments with diethyl ether. In no case did a crystalline residue result. Example 5: Preparation process for novel salt forms
[0372] a) Hydrochloride salt form HCl-NF1:
[0373] i) Experiments from acetone and subsequent crystallization of the resulting amorphous material from ethanol:
[0374] Approximately 49 mg of the free base and 108 μL of hydrochloric acid (32%, diluted 1:10 in acetone) were dissolved in 2 mL of acetone at rt. No spontaneous precipitation was observed. The vial was left uncapped in a fume hood to allow the solvent to evaporate. A glassy residue was obtained. To this residue 1 mL of ethanol was added and a clear solution was obtained at 50° C., which was cooled to 5° C. within 16 h. No crystallization occurred. The vial with the clear solution was left uncapped in a larger vial with diethyl ether at the bottom as an anti-solvent reservoir for the vapor diffusion process. Again, a glassy residue was obtained. To the solution with the glassy residue, a few mg of seeds of the hydrochloride salt form HCl-NF2 were added. Within 1 min, a white powder crystallized. 1 mL of diethyl ether was added to the suspension, which was subjected to solid- / liquid separation by centrifugation using PE centrifuge vials.
[0375] ii) Direct experiment with ethanol
[0376] Approximately 1 g of the free base was completely dissolved in 10 mL of ethanol under reflux conditions in a 100 mL round bottom flask on a water bath on a heating plate. No spontaneous precipitation was observed upon addition of 22 μL of hydrochloric acid (32%). The solution was cooled to 70° C., 60° C., and 50° C., respectively. No precipitation occurred at any step. At 50° C. and 40° C., seeds of HCl-NF1 were added to the solution, respectively. At both temperatures, the seeds dissolved. The solution was cooled to 20° C., and no precipitation occurred. At 20° C., a few mg of seeds of HCl-NF1 were added, and small fragments formed. The solution was cooled to 5° C., and again a few mg of seeds of HCl-NF1 were added. A cloudy solution was obtained. To the cloudy solution, 20 mL of diethyl ether was added, and a fine suspension was observed. Further addition of 20 mL of diethyl ether resulted in a yellow doughy residue on the glass surface. Then 45 mL of diethyl ether was added and stirred overnight. The yellow sticky residue was scraped into the solution with a spatula and 10 mL of diethyl ether was dosed. The bath was heated to 40° C. and the sticky residue was stirred for 20 min. The batch was then cooled to 40° C.-5° C. within 1 h and a further 5 mL of diethyl ether was added at 25° C. A fine white crystallisate was obtained. Solid / liquid separation was achieved by centrifugation using a PE centrifuge vial. The obtained powder was dried at RT under nitrogen flow for approximately 2 h.
[0377] b) Hydrochloride form HCl-NF2:
[0378] Approximately 20 mg of free base and 45 μL of hydrochloric acid (32%, diluted 1:10 in acetone) were dissolved in 0.8 mL of acetone at rt. No spontaneous precipitation was observed. The vial was left uncapped in a fume hood to allow the solvent to evaporate. A glassy residue was obtained. To this residue was added 0.4 mL of ethanol and a clear solution was obtained at 50° C., which was cooled to 5° C. within 16 h. No crystallization occurred. The vial with the clear solution was left uncapped in a larger vial with diethyl ether at the bottom as an anti-solvent reservoir for the vapor diffusion process. A white residue was obtained, which was subjected to solid- / liquid separation by centrifugation using PE centrifuge vials.
[0379] c) Hydrochloride salt form HCl-NF3:
[0380] Approximately 25 mg of the free base and 56 μL of hydrochloric acid (32%, diluted 1:10 in acetone) were dissolved in 0.8 mL of acetone at rt. No spontaneous precipitation was observed. The vial was left uncapped in a fume hood to allow the solvent to evaporate. 250 μL of diethyl ether was added dropwise to the solution, which became cloudy. A few mg of seeds of the form HCl-NF1 and another 250 μL of diethyl ether were added. After a few minutes, a white residue was obtained that was stirred overnight. The resulting suspension was subjected to solid- / liquid separation by centrifugation using PE centrifuge vials.
[0381] d) Hydrobromide salt form HBr-NF1:
[0382] Approximately 51 mg of the free base and 133 μL of hydrobromic acid (48%, diluted 1:10 in acetone) were dissolved in 2 mL of acetone at rt. No spontaneous precipitation was observed. The vial was left uncapped in a fume hood to allow the solvent to evaporate. A glassy residue was obtained. 1 mL of ethanol was added to this residue, resulting in a clear solution. The vial with the clear solution was left uncapped in a larger capped vial with diethyl ether at the bottom as an anti-solvent reservoir for the vapor diffusion process. To the solution with the glassy residue, a few mg of seeds of the hydrobromide salt form HBr-NF2 were added. Within 1 min, a white powder crystallized. 1 mL of diethyl ether was added to the suspension, which was subjected to solid- / liquid separation by centrifugation using PE centrifuge vials.
[0383] e) Hydrobromide salt form HBr-NF2:
[0384] Approximately 20 mg of the free base and 50 μL of hydrobromic acid (48%, diluted 1:10 in acetone) were dissolved in 0.8 mL of acetone at rt. No spontaneous precipitation was observed. The vial was left uncapped in a fume hood to allow the solvent to evaporate. A glassy residue was obtained. To this residue was added 0.4 mL of ethanol and a clear solution was obtained at 50° C., which was cooled to 5° C. within 16 h. No crystallization occurred. The vial with the clear solution was left uncapped in a larger vial with diethyl ether at the bottom as an anti-solvent reservoir for the vapor diffusion process. A white residue was obtained, which was subjected to solid- / liquid separation by centrifugation using PE centrifuge vials.
[0385] f) Oxalate form Oxalic acid-NF1:
[0386] i) Experiments from acetone and subsequent crystallization of the resulting amorphous material from ethanol:
[0387] Approximately 19 mg of the free base was dissolved in 0.8 mL of acetone at rt and approximately 5 mg of oxalic acid was added to the solution. No spontaneous precipitation was observed. The vial was left uncapped in a fume hood to allow the solvent to evaporate. A glassy residue was obtained. 0.4 mL of ethanol was added to this residue and a clear solution was obtained at 50° C. which was cooled to 5° C. within 16 h. No crystallization occurred. The vial with the clear solution was left uncapped in a larger vial with diethyl ether at the bottom as an anti-solvent reservoir for the vapor diffusion process. A white residue was obtained which was subjected to solid- / liquid separation by centrifugation using PE centrifuge vials.
[0388] ii) Directly from acetone by anti-solvent precipitation
[0389] About 989 mg of the free base was completely dissolved in 15 mL of acetone under reflux conditions in a 250 mL round bottom flask on a water bath on a heating plate. No spontaneous precipitation was observed upon addition of 202 mg of oxalic acid dissolved in 1 mL of acetone. A few mg of oxalic acid-NF1 seeds were added to the solution, resulting in a cloudy solution. The temperature of the water bath was set to 60 degrees and an additional mg of form oxalic acid-NF1 seeds were added. The temperature of the water bath was lowered to 40°C and a clear solution containing fine white particles was observed. At a temperature of 5°C (water bath), a clear solution with fine white particles and dark chunks was obtained. Diethyl ether was added dropwise to 25 mL of the solution and during the addition the solution showed localized white precipitation, then a cloudy solution, and finally a sticky yellow residue on the glass wall. After a fast dose of another 100 mL of diethyl ether, a white cloudy solution and a sticky yellow residue on the wall was obtained. A few more mg of seeds of form oxalic acid-NF1 and 10 mL of diethyl ether were added to the suspension and heated to RT. The resulting white suspension was cooled again to 5° C. At this temperature, solid / liquid separation was achieved by centrifugation using PE centrifuge vials. The resulting powder was dried under nitrogen flow at RT for approximately 2 h.
[0390] g) Maleate form Maleic acid-NF1:
[0391] i) Experiments from THF / water followed by crystallization of the resulting amorphous material from 2-propanol:
[0392] Approximately 21 mg of the free base was dissolved in a mixture of 500 μL THF + 1 mL water at 50° C. and approximately 6 mg of maleic acid was added to the solution. No spontaneous precipitation was observed. The solution was cooled to 5° C. and no crystallization occurred. The vial was left uncovered in a fume hood to allow the solvent to evaporate. A glassy residue was obtained. This residue was dissolved in 2-propanol at 50° C. and cooled again to 5° C. No crystallization occurred and the vial was left in the refrigerator. After a few days, a white residue was obtained which was subjected to solid- / liquid separation by centrifugation using PE centrifuge vials.
[0393] ii) Directly from toluene by cooling crystallization:
[0394] Approximately 19 mg of the free base was dissolved in 1 mL of toluene at 80° C., and approximately 5 mg of maleic acid was added to the solution. No spontaneous precipitation was observed. The solution was cooled to 5° C. A white powder was obtained, which was subjected to solid- / liquid separation by centrifugation using a PE centrifuge vial.
[0395] 1H NMR (500 MHz, DMSO-d6) d 8.16 (s, 1H), 7.46 - 7.41 (m, 2H), 7.27 - 7.24 (m, 2H), 7.21 - 7.17 (m, 1H), 7.16 - 7.11 (m, 4H), 6.80 (dd, J = 16.7, 10.5 Hz, 1H), 6.40 - 6.21 (m, 2H), 6.12 (s, 2H), 6.09 (dd, J = 16.7, 2.4 Hz, 1H), 5.66 (dd, J = 10.4, 2.4 Hz, 1H), 4.25 - 4.16 (m, 1H), 3.96 - 3.86 (m, 1H), 3.61 (dd, J = 20.6, 6.4 Hz, 2H), 3.28 - 3.21 (m, 1H), 2.93 - 2.85 (m, 1H), 1.76 - 1.68 (m, 2H), 1.67 - 1.47 (m, 2H)
[0396] h) Maleate form Maleic acid-NF2:
[0397] Approximately 19 mg of the free base was dissolved in 0.8 mL of acetone at rt and approximately 5 mg of maleic acid was added to the solution. No spontaneous precipitation was observed. The vial was left uncapped in a fume hood to allow the solvent to evaporate. A glassy residue was obtained. To this residue 0.4 mL of ethanol was added and a clear solution was obtained at 50° C. which was cooled to 5° C. within 16 h. No crystallization occurred. The vial with the clear solution was left uncapped in a larger vial with diethyl ether at the bottom as an anti-solvent reservoir for the vapor diffusion process. A white residue was obtained which was subjected to solid- / liquid separation by centrifugation using PE centrifuge vials.
[0398] 1H NMR (500 MHz, DMSO-d6) d 8.14 - 8.10 (m, 1H), 7.45 - 7.41 (m, 2H), 7.27 - 7.24 (m, 2H), 7.21 - 7.16 (m, 1H), 7.16 - 7.09 (m, 4H), 6.80 (dd, J = 16.7, 10.5 Hz, 1H), 6.10 (s, 2H), 6.11 - 6.07 (m, 1H), 6.30 - 5.76 (m, 2H), 5.66 (dd, J = 10.5, 2.4 Hz, 1H), 4.23 - 4.16 (m, 1H), 3.94 - 3.86 (m, 1H), 3.60 (dd, J = 20.7, 6.5 Hz, 2H), 3.46 - 3.37 (m, 1H), 2.93 - 2.85 (m, 1H), 1.75 - 1.67 (m, 2H), 1.67 - 1.46 (m, 2H)
[0399] i) Fumarate form Fumaric acid NF1:
[0400] Approximately 6 mg of fumaric acid-NF2 was weighed into a 40 μL aluminum pan and heated to approximately 130° C. in a DSC oven for desolvation. DSC runs were obtained on a Mettler-Toledo DSC821e at a heating rate of 5 K / min using nitrogen purge gas at 50 mL / min.
[0401] 1H NMR (500 MHz, DMSO-d6) d 7.96 (s, 1H), 7.45 - 7.40 (m, 2H), 7.25 - 7.22 (m, 2H), 7.20 - 7.15 (m, 1H), 7.14 - 7.10 (m, 4H), 6.79 (dd, J = 16.7, 10.5 Hz, 1H), 6.58 (s, 2H), 6.09 (dd, J = 16.7, 2.5 Hz, 1H), 5.65 (dd, J = 10.5, 2.4 Hz, 1H), 5.59 - 5.52 (m, 2H), 5.20 (t, J = 6.4 Hz, 1H), 4.21 - 4.15 (m, 1H), 3.93 - 3.85 (m, 1H), 3.58 (dd, J = 21.0, 6.5 Hz, 2H), 3.40 - 3.18 (m, 1H), 2.94 - 2.86 (m, 1H), 1.74 - 1.67 (m, 2H), 1.65 - 1.48 (m, 2H)
[0402] j) Fumarate form Fumaric acid-NF2:
[0403] Approximately 20 mg of the free base was dissolved in 1 mL of toluene at 80° C., and approximately 5 mg of fumaric acid was added to the solution. No spontaneous precipitation was observed. The solution was cooled to 5° C. A white powder was obtained, which was subjected to solid- / liquid separation by centrifugation using PE centrifuge vials.
[0404] 1H NMR (500 MHz, DMSO-d6) d 7.96 (s, 1H), 7.44 - 7.39 (m, 2H), 7.27 - 7.22 (m, 2H), 7.19 - 7.10 (m, 5H), 6.79 (dd, J = 16.7, 10.5 Hz, 1H), 6.62 (s, 2H), 6.09 (dd, J = 16.7, 2.4 Hz, 1H), 5.65 (dd, J = 10.5, 2.4 Hz, 1H), 5.60 - 5.51 (m, 2H), 5.20 (t, J = 6.4 Hz, 1H), 4.22 - 4.15 (m, 1H), 3.93 - 3.86 (m, 1H), 3.62 - 3.55 (m, 2H), 3.25 (s, 1H), 2.94 - 2.86 (m, 1H), 1.75 - 1.66 (m, 2H), 1.66 - 1.47 (m, 2H)
[0405] k) Fumarate form Fumaric acid-NF3:
[0406] Approximately 20 mg of the free base was dissolved in 0.8 mL of acetone at rt and approximately 5 mg of fumaric acid was added to the solution. No spontaneous precipitation was observed. The solution was cooled to 5° C. The vial was left uncapped in a fume hood to allow the solvent to evaporate. A glassy residue and an off-white powder fraction were obtained. After solid- / liquid separation by centrifugation using PE centrifuge vials, the off-white powder was extracted.
[0407] 1H NMR (500 MHz, DMSO-d6) d 7.96 (s, 1H), 7.44 - 7.40 (m, 2H), 7.25 - 7.22 (m, 2H), 7.19 - 7.15 (m, 1H), 7.14 - 7.10 (m, 4H), 6.79 (dd, J = 16.7, 10.5 Hz, 1H), 6.62 (s, 2H), 6.09 (dd, J = 16.7, 2.4 Hz, 1H), 5.65 (dd, J = 10.5, 2.4 Hz, 1H), 5.58 - 5.54 (m, 2H), 5.20 (t, J = 6.4 Hz, 1H), 4.22 - 4.15 (m, 1H), 3.93 - 3.86 (m, 1H), 3.64 - 3.55 (m, 2H), 3.27 - 3.19 (m, 1H), 2.95 - 2.86 (m, 1H), 1.75 - 1.67 (m, 2H), 1.66 - 1.47 (m, 2H)
[0408] l) Fumarate form Fumaric acid-NF4:
[0409] Approximately 50 mg of the free base was dissolved in 2.5 mL of 2-propanol at rt and approximately 13 mg of fumaric acid was added to the solution. No spontaneous precipitation was observed. The vial was left uncapped in a fume hood to allow the solvent to evaporate. A glassy residue was obtained. 2-propanol was added and a suspension was obtained, which was subjected to solid-liquid separation by centrifugation using PE centrifuge vials.
[0410] m) Fumarate form Fumaric acid-NF5 (mixture with Fumaric acid-NF1):
[0411] The clear mother liquor of a fumarate salt crystallization experiment in 2-propanol with an original composition of about 20 mg of free base, 5 mg of fumaric acid, and 1 mL of 2-propanol was evaporated at rt. A glassy residue and a fraction of white crystals were obtained. The white crystals were extracted for analysis.
[0412] 1H NMR (500 MHz, DMSO-d6) d 7.96 (s, 1H), 7.45 - 7.39 (m, 2H), 7.26 - 7.22 (m, 2H), 7.19 - 7.14 (m, 1H), 7.14 - 7.10 (m, 4H), 6.80 (dd, J = 16.7, 10.5 Hz, 1H), 6.62 (s, 2H), 6.09 (dd, J = 16.7, 2.4 Hz, 1H), 5.65 (dd, J = 10.5, 2.4 Hz, 1H), 5.60 - 5.53 (m, 2H), 5.20 (t, J = 6.4 Hz, 1H), 4.22 - 4.14 (m, 1H), 3.94 - 3.85 (m, 1H), 3.58 (dd, J = 21.0, 6.4 Hz, 2H), 3.28 - 3.19 (m, 1H), 2.95 - 2.86 (m, 1H), 1.75 - 1.67 (m, 2H), 1.66 - 1.48 (m, 2H)
[0413] n) Mesylate form Mesylate-NF1:
[0414] Approximately 20 mg of the free base was dissolved in 0.8 mL of acetone at rt and approximately 3 μL of methanesulfonic acid was added to the solution. No spontaneous precipitation was observed. The vial was left uncapped in a fume hood to allow the solvent to evaporate. A glassy residue was obtained. 0.4 mL of ethanol was added to this residue and a clear solution was obtained at 50° C. which was cooled to 5° C. within 16 h. No crystallization occurred. The vial with the clear solution was left uncapped in a larger vial with diethyl ether at the bottom as an anti-solvent reservoir for the vapor diffusion process. A white residue was obtained which was subjected to solid- / liquid separation by centrifugation using PE centrifuge vials.
[0415] 1H NMR (500 MHz, DMSO-d6) d 8.30 (s, 1H), 7.47 - 7.42 (m, 2H), 7.29 - 7.25 (m, 2H), 7.22 - 7.18 (m, 1H), 7.18 - 7.11 (m, 4H), 6.92 - 6.69 (m, 2H), 6.81 (dd, J = 16.7, 10.5 Hz, 1H), 6.10 (dd, J = 16.7, 2.4 Hz, 1H), 5.67 (dd, J = 10.4, 2.4 Hz, 1H), 4.27 - 4.19 (m, 1H), 3.97 - 3.88 (m, 1H), 3.69 - 3.57 (m, 2H), 3.28 - 3.19 (m, 1H), 2.92 - 2.83 (m, 1H), 2.30 (s, 3H), 1.76 - 1.67 (m, 2H), 1.67 - 1.46 (m, 2H) Example 6: Solubility Data for the Free Base Form
[0416] Thermodynamic solubility data for free base forms A1 and A2 at 37°C
[0417] Approximately 10-20 mg of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone was weighed into a 4 mL glass vial. 1 mL of FaSSIF medium (pH 6.5) or USP phosphate buffer pH 7.4 was added and the suspension was shaken at 37 °C and 450 rpm for 24 h. After 1 h, 6 h and 24 h the vials were inspected to determine the presence of undissolved compound and pH. If necessary, the pH was adjusted after 1 h and 6 h. Solid-liquid separation was performed using a 1 mL syringe and a 0.2 μm syringe filter. The clear filtrate was analyzed by HPLC after appropriate dilution to determine the amount of dissolved API.
[0418] The results from the thermodynamic solubility determinations are summarized below. [Table 18] Example 7: Mini-dissolution data of new salt forms versus parent
[0419] Approximately 10-20 mg of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone was weighed into a glass vial. 7 mL of FaSSIF medium (pH 6.5, pre-warmed to 37° C.) was added and the suspension was shaken at 37° C. and 450 rpm. After 30, 60 and 120 min, 1 mL of the suspension was withdrawn and filtered through a 0.2 μm syringe filter. The clear filtrate was analyzed by HPLC after appropriate dilution to determine the amount of dissolved API.
[0420] The results from the mini-dissolution study are summarized below. [Table 19] [Table 20]
[0421] While numerous embodiments of the invention have been described herein, it will be apparent that the basic examples may be modified to provide other embodiments that utilize the compounds and methods of the invention. It will therefore be appreciated that the scope of the invention is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example.
Claims
1. Compound 1 【Chemical 1】 or a pharmaceutically acceptable salt thereof.
2. 2. The solid form of claim 1, wherein the solid form is crystalline anhydrous form A2.
3. 3. The solid form of claim 2, crystalline form A2, wherein form A2 is characterized by two or more of the following XRPD peaks at 17.0±0.2°, 18.7±0.2°, and 21.7±0.2° degrees 2θ.
4. 3. The solid form of claim 2, wherein Form A2 is characterized by four or more of the following 2θ XRPD peaks: 7.5±0.2°, 10.8±0.2°, 17.0±0.2°, 17.5±0.2°, 18.7±0.2°, 20.5±0.2°, 21.7±0.2°, 22.3±0.2°, 23.6±0.2°, and 24.0±0.2° degrees.
5. 3. The solid form of claim 2, having crystalline form A2 and space group P-1 with lattice parameters a=9.5±0.1 Å, b=10.7±0.1 Å, c=12.8±0.1 Å, and aα=71.0±0.1°, β=68.9±0.1°, γ=71.9±0.1°.
6. 2. The solid form of claim 1, wherein form A1 is characterized by two or more of the following 2θ XRPD peaks: 17.1±0.2°, 17.4±0.2°, 18.8±0.2°, 20.0±0.2°, and 21.1±0.2° degrees.
7. 7. The solid form of claim 6, wherein Form A1 is characterized by four or more of the following 2θ XRPD peaks: 17.1±0.2°, 17.4±0.2°, 18.8±0.2°, 20.0±0.2°, and 21.1±0.2° degrees.
8. 2. The solid form of claim 1, having crystalline form A1, having space group P21 / n with a=12.8±0.1 Å, b=12.9±0.1 Å, c=28.6±0.1 Å, and β=98.0±0.1° (with α=γ=90°).
9. 2. The solid form of claim 1, wherein the solid form is selected from the HCl salt HCl-NF1 of Compound 1, the HCl salt HCl-NF2 of Compound 1, the HCl salt HCl-NF3 of Compound 1, the HBr salt HBr-NF1 of Compound 1, the HBr salt HBr-NF2 of Compound 1, the oxalate salt form oxalic acid-NF1 of Compound 1, the maleate salt form maleic acid-NF1 of Compound 1, the maleate salt form maleate-NF2 of Compound 1, the fumarate salt form fumaric acid-NF1 of Compound 1, the fumarate salt form fumaric acid-NF2 of Compound 1, the fumarate salt form fumaric acid-NF3 of Compound 1, the fumarate salt form fumaric acid-NF4 of Compound 1, the fumarate salt form fumaric acid-NF5 of Compound 1, and the mesylate salt form mesylate-NF1 of Compound 1.
10. 10. The HCl-NF1 salt of claim 9, characterized by two or more of the following 2θ XRPD peaks: 15.7±0.2°, 19.1±0.2°, 20.3±0.2°, and 20.8±0.2° degrees.
11. 10. The HCl-NF2 salt of claim 9, characterized by two or more of the following 2θ XRPD peaks: 7.8±0.2°, 13.0±0.2°, and 15.6±0.2° degrees.
12. 10. The HCl-NF3 salt of claim 9, characterized by two or more of the following 2θ XRPD peaks: 14.8±0.2°, 16.8±0.2°, 20.1±0.2°, and 20.4±0.2° degrees.
13. 10. The HBr-NF1 salt of claim 9, characterized by two or more of the following 2θ XRPD peaks: 6.9±0.2°, 19.1±0.2°, 20.4±0.2°, 20.8±0.2°, and 21.9±0.2° degrees.
14. 10. The HBr-NF2 salt of claim 9, characterized by two or more of the following 2θ XRPD peaks: 4.9±0.2°, 13.2±0.2°, and 20.0±0.2° degrees.
15. 10. The oxalic acid-NF1 of claim 9 characterized by two or more of the following 2θ XRPD peaks: 16.2±0.2°, 17.7±0.2°, 18.6±0.2°, 21.1±0.2°, and 21.3±0.2° degrees.
16. 10. The maleic acid-NF1 salt of claim 9, characterized by two or more of the following 2θ XRPD peaks: 18.1±0.2°, 19.1±0.2°, 20.8±0.2°, and 24.8±0.2° degrees.
17. 10. The maleate-NF2 salt of claim 9, characterized by two or more of the following 2θ XRPD peaks: 10.8±0.2°, 17.1±0.2°, 19.2±0.2°, and 20.7±0.2° degrees.
18. 10. The fumaric acid NF1 salt of claim 9, characterized by two or more of the following 2θ XRPD peaks: 9.0±0.2°, 17.0±0.2°, 18.±0.2°, and 22.1±0.2° degrees.
19. 10. The mesylate-NF1 salt of claim 9, characterized by two or more of the following 2θ XRPD peaks: 18.7±0.2°, 19.5±0.2°, and 21.1±0.2° degrees.
20. A pharmaceutical composition comprising a solid form of Compound 1 of claim 1 and a pharmaceutically acceptable adjuvant, carrier, or vehicle.
21. 10. A method for treating a BTK-mediated disorder in a patient in need thereof, comprising administering to the patient a solid form of compound 1 of claim 1.
22. 10. Use of a solid form of compound 1 according to claim 1 or a physiologically acceptable salt thereof for the production of a medicament for the prophylactic or therapeutic treatment of a BTK-mediated disorder.
Citation Information
Patent Citations
Compositions and methods for producing pyrimidines and pyrimidine compounds having BTK inhibitory activity
JP2014517016A
A novel crystalline form of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone
JP2020509014A
Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity
WO2017079542A1
